<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2403210641
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        EZETROL 10 mg tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        EZETIMIBE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        159.80
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MSD International GmbH (Singapore Branch)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MSD International GmbH (Singapore Branch)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Organon Pharma UK Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C10AX09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>EZETROL is a medicine to lower increased levels of cholesterol.</p><p>&nbsp;</p><p>EZETROL lowers levels of total cholesterol, &ldquo;bad&rdquo; cholesterol (LDL cholesterol), and fatty substances called triglycerides in the blood. In addition, EZETROL raises levels of &ldquo;good&rdquo; cholesterol (HDL cholesterol).</p><p>&nbsp;</p><p>Ezetimibe, the active ingredient of EZETROL, works by reducing the cholesterol absorbed in your digestive tract.</p><p>&nbsp;</p><p>EZETROL adds to the cholesterol-lowering effect of statins, a group of medicines that reduce the cholesterol your body makes by itself.</p><p>&nbsp;</p><p>Cholesterol is one of several fatty substances found in the bloodstream. Your total cholesterol is made up mainly of LDL and HDL cholesterol.</p><p>&nbsp;</p><p>LDL cholesterol is often called &ldquo;bad&rdquo; cholesterol because it can build up in the walls of your arteries forming plaque. Eventually this plaque build-up can lead to a narrowing of the arteries. This narrowing can slow or block blood flow to vital organs such as the heart and brain. This blocking of blood flow can result in a heart attack or stroke.</p><p>&nbsp;</p><p>HDL cholesterol is often called &ldquo;good&rdquo; cholesterol because it helps keep the bad cholesterol from building up in the arteries and protects against heart disease.</p><p>&nbsp;</p><p>Triglycerides are another form of fat in your blood that may increase your risk for heart disease.</p><p>&nbsp;</p><p>It is used for patients who cannot control their cholesterol levels by cholesterol lowering diet alone. You should stay on your cholesterol lowering diet while taking this medicine.</p><p>&nbsp;</p><p><em><u>EZETROL</u></em><em><u> </u></em><em><u>is used in addition to your cholesterol lowering diet if you have:</u></em></p><p><em>&nbsp;</em></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->a raised cholesterol level in your blood (primary hypercholesterolaemia [heterozygous familial and non-familial])</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->together with a statin, when your cholesterol level is not well controlled with a statin alone</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->alone, when statin treatment is inappropriate or is not tolerated</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->a hereditary illness (homozygous familial hypercholesterolaemia) that increases the cholesterol level in your blood. You will also be prescribed a statin and may also receive other treatments.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->a hereditary illness (homozygous sitosterolaemia, also known as phytosterolaemia) that increases the levels of plant sterols in your blood.</p><p>&nbsp;</p><p>If you have heart disease, EZETROL combined with cholesterol-lowering medicines called statins reduces the risk of heart attack, stroke, surgery to increase heart blood flow, or hospitalisation for chest pain.</p><p>&nbsp;</p><p>EZETROL does not help you lose weight.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>If you use EZETROL together with a statin, please read the package leaflet of that particular medicine.</p><p>&nbsp;</p><p>Do not take EZETROL if:</p><p><strong>&nbsp;</strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->you are allergic (hypersensitive) to ezetimibe or any of the other ingredients of this medicine (see Section 6: Contents of the pack and other information).</p><p>&nbsp;</p><p>Do not take EZETROL together with a statin if:</p><p><strong>&nbsp;</strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->you currently have liver problems.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->you are pregnant or breast-feeding.</p><p>&nbsp;</p><p>Warnings and precautions</p><p><strong>&nbsp;</strong></p><p>Talk to your doctor or pharmacist before taking EZETROL.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Tell your doctor about all your medical conditions including allergies.</p><p>&nbsp;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Your doctor should do a blood test before you start taking EZETROL with a statin. This is to check how well your liver is working.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Your doctor may also want you to have blood tests to check how well your liver is working after you start taking EZETROL with a statin.</p><p>&nbsp;</p><p>If you have moderate or severe liver problems, EZETROL is not recommended.</p><p>&nbsp;</p><p>The safety and efficacy of the combined use of EZETROL and certain cholesterol lowering medicines, the fibrates have not been established.</p><p>&nbsp;</p><p>Children and adolescents</p><p>Do not give this medicine to children and adolescents (6 to 17 years of age) unless prescribed by a specialist because there are limited data on safety and efficacy. Do not give this medicine to children less than 6 years old because there is no information in this age group.</p><p>&nbsp;</p><p>Other medicines and EZETROL</p><p><strong>&nbsp;</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. In particular, tell your doctor if you are taking medicine(s) with any of the following active ingredients:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ciclosporin (often used in organ transplant patients)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->medicines with an active ingredient to prevent blood clots, such as warfarin, phenprocoumon, acenocoumarol or fluindione (anticoagulants)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->colestyramine &nbsp;(also &nbsp;used &nbsp;to &nbsp;lower &nbsp;cholesterol), &nbsp;because &nbsp;it &nbsp;affects &nbsp;the &nbsp;way EZETROL works</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->fibrates (also used to lower cholesterol)</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p><strong>&nbsp;</strong></p><p>Do not take EZETROL with a statin if you are pregnant, are trying to get pregnant or think you may be pregnant. If you get pregnant while taking EZETROL with a statin, stop taking both medicines immediately and tell your doctor.</p><p>&nbsp;</p><p>There is no experience from the use of EZETROL without a statin during pregnancy. Ask your doctor for advice before using EZETROL if you are pregnant.</p><p>&nbsp;</p><p>Do not take EZETROL with a statin if you are breast-feeding, because it is not known if the medicines are passed into breast milk.</p><p>&nbsp;</p><p>EZETROL without a statin should not be used if you are breast-feeding. Ask your doctor for advice.</p><p>&nbsp;</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>&nbsp;</p><p>Driving and using machines</p><p><strong>&nbsp;</strong></p><p>EZETROL is not expected to interfere with your ability to drive or to use machinery. However, it should be taken into account that some people may get dizzy after taking EZETROL.</p><p>&nbsp;</p><p>EZETROL contains lactose.</p><p><strong>&nbsp;</strong></p><p>EZETROL tablets contain a sugar called lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Continue taking your other cholesterol-lowering medicines unless your doctor tells you to stop. You should check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Before starting EZETROL, you should be on a diet to lower your cholesterol.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->You should keep on this cholesterol lowering diet whilst taking EZETROL. The recommended dose is one EZETROL 10 mg Tablet by mouth once a day. Take EZETROL at any time of the day. You can take it with or without food.</p><p>If your doctor has prescribed EZETROL along with a statin, both medicines can be taken at the same time. In this case, please read the dosage instructions in the package leaflet of that particular medicine.</p><p>&nbsp;</p><p>If your doctor has prescribed EZETROL along with another medicine for lowering cholesterol containing the active ingredient colestyramine or any other medicine containing &nbsp;bile acid sequestrant, you should take EZETROL at least 2 hours before or 4 hours after taking the bile acid sequestrant.</p><p>&nbsp;</p><p>If you take more EZETROL than you should</p><p><strong>&nbsp;</strong></p><p>Please contact your doctor or pharmacist.</p><p>&nbsp;</p><p>If you forget to take EZETROL</p><p><strong>&nbsp;</strong></p><p>Do not take a double dose to make up for a forgotten tablet, just take your normal amount of EZETROL at the usual time the next day.</p><p>&nbsp;</p><p>If you stop taking EZETROL</p><p><strong>&nbsp;</strong></p><p>Talk to your doctor or pharmacist because your cholesterol may rise again.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>The following terms are used to describe how often side effects have been reported:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Very common (may affect more than 1 of 10 patients)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Common (may affect up to 1 of 10 patients)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Uncommon (may affect up to 1 of 100 patients)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Rare (may affect up to 1 of 1,000 patients)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Very rare (may affect up to 1 of 10,000 patients, including isolated reports).</p><p>&nbsp;</p><p>Contact your doctor immediately if you experience unexplained muscle pain, tenderness, or weakness. This is because on rare occasions, muscle problems, including muscle breakdown resulting in kidney damage, can be serious and may become a potentially life-threatening condition.</p><p><strong>&nbsp;</strong></p><p>Allergic reactions, including swelling of the face, lips, tongue, and/or throat that may cause difficulty in breathing or swallowing (which requires treatment right away) have been reported in general use.</p><p>&nbsp;</p><p>When used alone, the following side effects were reported: Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain; diarrhoea; flatulence; feeling tired.</p><p>Uncommon: elevations in some laboratory blood tests of liver (transaminases) or muscle (CK) function; cough; indigestion; heartburn; nausea; joint pain; muscle spasms; neck pain; decreased appetite, pain, chest pain, hot flush; high blood pressure.</p><p>&nbsp;</p><p>Additionally, when used with a statin, the following side effects were reported:</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; elevations&nbsp;&nbsp;&nbsp;&nbsp; in&nbsp;&nbsp;&nbsp; some&nbsp;&nbsp;&nbsp; laboratory&nbsp;&nbsp;&nbsp;&nbsp; blood tests&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of&nbsp;&nbsp;&nbsp; liver&nbsp;&nbsp;&nbsp; function (transaminases); headache; muscle pain, tenderness or weakness.</p><p>Uncommon: tingling sensation; dry mouth; itching; rash; hives; back pain; muscle weakness; pain in arms and legs; unusual tiredness or weakness; swelling, especially in the hands and feet.</p><p>&nbsp;</p><p>When used with fenofibrate, the following common side effect was reported: abdominal pain.</p><p>&nbsp;</p><p>Additionally, the following side effects have been reported in general use: dizziness; muscle aches; liver problems; allergic reactions including rash and hives; raised red rash, sometimes with target-shaped lesions (erythema multiforme); muscle pain, tenderness or weakness; muscle breakdown; gallstones or inflammation of the gallbladder (which may cause abdominal pain, nausea, vomiting); inflammation of the pancreas often with severe abdominal pain; constipation, reduction in blood &nbsp;cell counts, which may cause bruising/bleeding (thrombocytopaenia); tingling sensation; depression: unusual tiredness or weakness; shortness of breath.</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly &ldquo;The National Pharmacovigilance and Drug Safety Centre (NPC)&rdquo;.</p><p>By reporting side effects, you can help provide more information</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Keep this medicine out of the sight and reach of children.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Do not use this medicine after the expiry date which is stated on the carton or container after &quot;EXP.&quot; The expiry date refers to the last day of that month.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Store below 30&deg;C.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Store in the original package .</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The active substance is ezetimibe. Each tablet contains 10 mg ezetimibe.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The&nbsp;&nbsp;&nbsp; other&nbsp;&nbsp;&nbsp; ingredients&nbsp;&nbsp;&nbsp;&nbsp; are:&nbsp;&nbsp;&nbsp; lactose&nbsp;&nbsp;&nbsp; monohydrate, microcrystalline&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cellulose, povidone, croscarmellose sodium, sodium laurilsulfate, magnesium stearate.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                EZETROL tablets are white to off-white, capsule-shaped tablets with code “414” on one side.Pack sizes:7, 10, 14, 20, 28, 30, 50, 98, 100 or 300 tablets in push-through blisters or unit dose peelable blisters;84 or 90 tablets in push-through blisters;50, 100 or 300 tablets in unit dose push-through blisters; Not all pack sizes may be available.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder:</strong></p><p>Merck Sharp &amp; Dohme Ltd. Hertford</p><p>Road, Hoddesdon</p><p>Hertfordshire EN11 9BU</p><p>United Kingdom</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>MSD International GmbH (Puerto Rico Branch) LLC,</p><p>Las Piedras Operations , Pridco Industrial Park,</p><p>State Road no. 183, Las Piedras, Puerto Rico</p><p>00771, Puerto Rico</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
This leaflet was last revised in February 2016
Version No. (02)

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ازيترول دواء يستخدم لخفض مستويات الكولسترول المرتفعة.</p><p>ازيترول يعمل على خفّض مستوى الكولسترول الكُلي، الكولسترول السيء (البروتين ُالشَّحْمِيُّ المنخفض الكَثافة) والمواد الدهنيّة المعروفة بالدهون الثلاثية في الدم. اضافة إلى ذلك، يرفع من مستويات الكولسترول الجيّد (البروتين ُالشَّحْمِيُّ المُرْتَفِعُ الكَثافَة).</p><p>تعمل المادة الفعالة في ازيترول، إزتيمايب، على خفض امتصاص الكولسترول في جهازك الهضمي.</p><p>يزيد ازيترول من المفعول المخفِّض للكولسترول لمواد الستاتين، وهي مجموعة من الأدوية التي تُخفّض الكولسترول التي يُنتجها جسمك.</p><p>يُعتبَر الكولسترول واحدًا من المواد الدهنيّة العديدة في مجرى الدم. الكولسترول الكُلي مؤلّف بشكل أساسي من الكولسترول السيء (البروتين &nbsp;الشَّحْمِيُّ &nbsp;المنخفض الكَثافة) والكولسترول الجيّد (البروتين &nbsp;الشَّحْمِيُّ المُرْتَفِعُ الكَثافَة).</p><p>غالبًا ما يُعرَف الكولسترول (البروتين ُالشَّحْمِيُّ المنخفض الكَثافة) بالكولسترول السيء لأنّه يتكدّس في جدران شرايينك فيشكّل لويحة قد تُضيّق مجاري الشرايين، ممّا قد يُبطئ تدفّق الدم أو يُعرقله فيمنع وصوله إلى الأعضاء الحيويّة، مثل القلب والدماغ. قد يُسبّب انسداد تدفّق الدم إلى سكتة أو نوبة قلبيّة.</p><p>أما الكولسترول (البروتين ُالشَّحْمِيُّ المُرْتَفِعُ الكَثافَة) فغالبًا ما يُعرَف بالكولسترول الجيّد لأنّه يُساهم في منع الكولسترول السيء من التكدّس في الشرايين ويحمي من أمراض القلب.</p><p>الدهون الثلاثية شكل آخر من المواد الدهنيّة في دمك التي قد تزيد من خطر تعرّضك لأمراض قلبيّة.</p><p>يُستخدَم هذا الدواء &nbsp;لدى المرضى الذين لا يُمكنهم السيطرة على مستويات الكولسترول من خلال مجرّد حمية غذائيّة مخّفضة للكولسترول. عليك الابقاء على الحمية المُخفِّضة للكولسترول عندما تتناول هذا الدواء.</p><p>&nbsp;</p><p><em><u>يُستخدَم ازيترول بالإضافة إلى الحمية المُخفِّضة للكولسترول في الحالات التالية:</u></em></p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->مستوى الكولسترول مرتفع في دمك (فرط كولسترول الدم الأولي) (متغاير الزيجوت العائلي وغير العائلي)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->مع مادة الستاتين، عندما لا تتمّ السيطرة بشكل جيّد على مستوى الكولسترول بواسطة مادة الستاتين وحدها</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->بمفرده، عندما لا يكون العلاج بالستاتين ملائمًا أو لا يمكن تحمله</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->مرض وراثي (فرط كولسترول الدم العائلي المتماثل الزيجوت) يزيد من مستوى الكولسترول في الدم. قد توصف لك مادة الستاتين وقد تتلقّى علاجات أخرى.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->مرض وراثي (وُجودُ السيتوستيرولِ في الدَّم المتماثل الزيجوت) يزيد من مستويات ستيرولات في دمك.</p><p>إذا كان لديك مرض في القلب، فإن ازيترول جنبًا إلى جنب مع الأدوية المخفضة للكولسترول التي تُدعى الستاتين يعمل على تقليل خطر الإصابة بالنوبات القلبية والسكتة الدماغية، و الحاجة إلى عملية جراحية لزيادة تدفق الدم من القلب، أو دخول المستشفى لعلاج آلام الصدر.</p><p>لا يُساعدك ازيترول على فقدان الوزن.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>إذا كنت تتناول ازيترول مع مادة الستاتين، يُرجى قراءة النشرة الداخلية لذلك المستحضر بالتحديد.</p><p><strong>&nbsp;</strong></p><p><strong>لا تأخذ ازيترول في الحالات التالية:</strong></p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كان لديك حساسيّة (حساسيّة مفرطة) من إزتيمايب أو من أيّ من المكوّنات الأخرى لهذا الدواء (راجع البند 6: معلومات إضافيّة ومحتوى العبوة).</p><p><strong>&nbsp;</strong></p><p><strong>لا تتناول الازيترول مع مادة ستاتين في الحالات التالية:</strong></p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت مُصابًا حاليًّا بمشاكل في الكبد.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنتِ امرأةً حاملًا أو مُرضعًا.</p><p><strong>&nbsp;</strong></p><p><strong>المخاطر و الاحتياطات </strong></p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->اطلع الطبيب على حالاتك الطبيّة الكاملة، بما في ذلك الحساسيّة.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->على طبيبك إخضاعك لفحص دم قبل أن تبدأ بتناول ازيترول مع مادة ستاتين وذلك للتأكّد من مدى كفاءة عمل الكبد.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->قد يطلب منك طبيبك أيضًا إجراء فحوصات دم للتأكّد من عمل كبدك بعد البدء بتناول ازيترول مع مادة ستاتين.</p><p>إذا كان لديك مشاكل كبد متوسطه&nbsp;أو حادة، لا يُوصى بتناول ازيترول.</p><p>لم يتم بعد إثبات السلامة والفاعليّة لاستخدام ازيترول مع بعض الأدوية المخفّضة للكولسترول، الفايبرات.</p><p>&nbsp;</p><p><strong>الأطفال والمراهقين</strong></p><p>يمنع إعطاء ازيترول للأطفال والمراهقين ما بين 6-17 سنة ، ما لم ييُوصي به الطبيب لأن المعلومات المتوافرة قليلة بخصوص السلامة و الكفاءة. يمنع إعطاء ازيترول للأطفال دون السادسة من العمر لعدم توافر معلومات لهذه الفئة العمرية.</p><p>&nbsp;</p><p><strong>الأدوية الأخرى وازيترول</strong></p><p>اخبر الطبيب أو الصيدلي إذا كنت تتناول أو تناولت مؤخّرًا أو سوف تتناول أي أدوية أخرى، بما في ذلك تلك التي لا تحتاج إلى وصفة طبيّة. &nbsp;اخبر الطبيب بشكل خاص إذا كنت تتناول دواءً/أدويةً تحتوي على أيّ من المكوّنات الفعالة التالية:</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->سيكلوسبورين (غالبًا ما يُستخدم لدى المرضى الذين يخضعون لزراعة الأعضاء)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الأدوية التي تحتوي على مواد فعالة التي تمنع تخثّر الدم، مثل الوارفارين، والفينبروكومون، والأسينوكومارول، والفلوينديون (مضادات التخثّر)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الكوليستيرامين (التي تُستخدَم أيضًا لخفض مستوى الكولسترول) لأنّه يؤثّر على طريقة عمل ازيترول</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الفايبرات (التي تُستخدَم أيضًا لخفض مستوى الكولسترول)</p><p><strong>&nbsp;</strong></p><p><strong>الحمل والرضاعة</strong></p><p>لا تتناولي ازيترول مع مادة ستاتين إذا كنتِ حاملًا، أو تُحاولين الحمل، أو تظنّين أنّك قد تكونين حاملًا. في حال حدوث الحمل وأنت تتناولين ازيترول مع مادة ستاتين، توقّفي عن تناول العلاجين على الفور واخبري الطبيب.</p><p>لا &nbsp;توجد تجارب سابقة لاستخدام ازيترول من دون مادة ستاتين خلال الحمل. اطلبي مشورة الطبيب قبل تناول ازيترول وأنت حامل.</p><p>لا تتناولي ازيترول مع مادة ستاتين إذا كنتِ م مُرضعًا لأنّه من غير المعروف إذا كانت الأدوية تنتقل إلى حليب الأم.</p><p>لا ينبغي أن تتناولي إزيترول من دون الستاتين إذا كنتِ مُرضعًا. اطلبي مشورة الطبيب.</p><p>اطلبي مشورة الطبيب أو الصيدلي قبل تناول أي دواء.</p><p>&nbsp;</p><p><strong>القيادة و استخدام الآلات </strong></p><p>لا يُتوقَّع أن يؤثّر ازيترول على قدرتك على القيادة أو على استخدام الآلات لكن، يجب الأخذ بعين الاعتبار أن بعض الأشخاص قد يُصابون بالدوارن بعد تناول ازيترول.</p><p>&nbsp;</p><p><strong>يحتوي ازيترول على اللاكتوز</strong></p><p>يحتوي ازيترول على مادة سكريّة تُعرَف باللاكتوز. في حال قال لك الطبيب بأنّك لا تحتمل بعض المواد السكريّة، عليك الاتصال بطبيبك قبل تناول هذا الدواء.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>دائمًا تناول ازيترول كما طلب منك الطبيب. تابع تناول الأدوية الأخرى المخفّضة لمستوى الكولسترول إلا إذا طلب منك الطبيب إيقافها. عليك مراجعة الطبيب أو الصيدلي في حال لم تكن متأكّدًا.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->قبل البدء بتناول ازيترول، يجب أن تتّبع حميّة غذائيّة لخفض مستوى الكولسترول لديك.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->عليك الابقاء على الحمية الغذائيّة المُخفّضة للكولسترول وأنت تتناول الازيترول.</p><p>الجرعة الموصى بها هي قرص ازيترول واحد 10 ملغم عبر الفم، مرةً واحدةً يوميًّا.</p><p>تناول ازيترول في أي وقت من اليوم. يُمكنك تناوله مع أو بلا طعام.</p><p>في حال وصف لك الطبيب تناول ازيترول مع مادة ستاتين، يُمكن تناول العلاجين في الوقت نفسه. في هذه الحالة، يُرجى قراءة النشرة الداخلية لذلك المستحضر بالتحديد.</p><p>في حال وصف لك الطبيب تناول ازيترول مع دواء آخر لخفض الكولسترول يحتوي على المادة الفعالة الكوليستيرامين أو على أي دواء آخر يحتوي على حامض الصفراء، عليك تناول ازيترول قبل ساعتَيْن من تناول حامض الصفراء أو بعد مرور 4 ساعات على تناوله.</p><p>&nbsp;</p><p><strong>في حال تناولت جرعة زائدة من ازيترول</strong></p><p>عليك الاتصال بالطبيب أو بالصيدلي.</p><p>&nbsp;</p><p><strong>في حال نسيت تناول جرعة ازيترول</strong></p><p>لا تتناول جرعةً زائدةً، بل اكتفِ بتناول جرعتك العاديّة من ازيترول في الوقت المُعتاد في اليوم التالي.</p><p>&nbsp;</p><p><strong>اذا توقفت عن تناول جرعة ازيترول</strong></p><p>تحدث إلى طبيبك أو الصيدلي لأنه من الممكن ارتفاع نسبة الكوليسترول لديك مجددا</p><p>إتّصل بالطبيب أو بالصيدلي في حال كان لديك أي أسئلة إضافيّة حول استخدام هذا الدواء.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>على غرار الأدوية كلّها، قد يُسبّب أعراضًا جانبيّةً، وإن كان لا يُصاب الجميع بها.</p><p>&nbsp;</p><p>تُستخدَم المصطلحات التالية لوصف وتيرة الإبلاغ عن الأعراض الجانبيّة:</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->شائعة جدًّا (قد تؤثّر على أكثر من مريض من أصل 10)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->شائعة (قد تؤثّر على مريض من أصل 10)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->غير شائعة (قد تؤثّر على مريض من أصل 100)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->نادرة (قد تؤثّر على مريض من أصل 1000)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->نادرة جدًّا (قد تؤثّر على مريض من أصل 10000، بما في ذلك حالات الإبلاغ المنفردة).</p><p>&nbsp;</p><p>اتّصل بالطبيب على الفور في حال أحسست بوهن أو ألم أو ضَعف غير مبرّر في العضلات. ففي حالات نادرة، قد تكون مشاكل العضلات، بما في ذلك فتور العضلات الذي يُسبب ضررًا في الكلى، خطيرةً وقد تهدّد الحياة.</p><p>في حالات الاستخدام العام، تمّ الابلاغ عن ردود فعل حساسيّة، بما في ذلك انتفاخ الوجه، والشفتَيْن، واللسان، و/أو الحنجرة التي قد تُسبّب صعوبة في التنفّس أو البلع (التي تحتاج إلى علاج على الفور).</p><p>&nbsp;</p><p><u>تمّ</u><u> الابلاغ عن الأعراض الجانبيّة التالية عند تناول ازيترول بمفرده:</u></p><p>الشائعة: ألم في البطن، إسهال، إنتفاخ البطن، شعور بالتعب.</p><p>غير الشائعة: ارتفاع في نتائج بعض فحوصات الدم المخبريّة للكبد (ناقلات الأمين) أو وظيفة (كرياتنين كاينيز) في العضلات؛ السعال؛ عسر الهضم؛ الحرقة؛ الغثيان؛ ألم المفاصل؛ تشنّجات عضليّة؛ ألم في العنق؛ انخفاض الشهيّة؛ ألم؛ ألم في الصدر؛ الهبّات السخنة؛ ارتفاع ضغط الدم.</p><p>&nbsp;</p><p><u>تمّ الابلاغ عن الأعراض الجانبيّة التالية عند تناول ازيترول مع مادة ستاتين:</u></p><p>الشائعة: ارتفاع في نتائج بعض فحوصات الدم المخبريّة للكبد (ناقلات الأمين)؛ صداع؛ ألم،&nbsp; أو وهن في عضلات.</p><p>غير الشائعة: شعور بالوخز؛ جفاف الفم ؛ حكاك؛ شرى؛ طفرة؛ ألم في الظهر؛ وهن في العضلات؛ ألم في الذراعَيْن والساقَيْن؛ وهن أو تعب غير اعتيادي؛ انتفاخ، لا سيّما في اليدَيْن أو القدمَيْن.</p><p>عند تناول ازيترول مع الفينوفيبرات، تمّ الابلاغ عن الأعراض الجانبيّة الشائعة التالية: ألم في البطن.</p><p>اضافة إلى ذلك، تمّ الابلاغ عن الأعراض الجانبيّة التالية بشكل عامّ: الدوخة؛ ألم في العضل؛ مشاكل في الكبد؛ ردود فعل حساسيّة، بما في ذلك الطفح الجلدي والشرى؛ الحمامة العديدة الأشكال؛ ألم أو إيلام أو وهن في العضل؛ فتور العضل؛ حصاة مراريّة أو إلتهاب المرارة (التي قد تُسبّب ألمًا في البطن، وغثيانًا، وتقيّؤًا)؛ والتهاب البنكرياس، الذي غالبًا ما يترافق مع ألم حاد في البطن؛ الامساك؛ انخفاض كميّات خلايا الدم الحمراء؛ ممّا قد يُسبّب التكدّم/النزيف (قلّة الصفيحات)؛ الشعور بالوخز، الاكتئاب ؛ الوهن أو التعب غير الاعتيادي؛ ضيق النفس.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>الابلاغ عن الأعراض الجانبيّة المحتملة:</strong></p><p>اتّصل بالطبيب أو الصيدلي في حال تعرّضك لأي أعراض جانبيّة محتملة بالإضافة إلى تلك غير المذكورة في هذه النشرة. يمكنك الإبلاغ عن الأعراض الجانبيّة مباشرة من خلال &quot; المركز الوطني للتيقظ والسلامة الدوائية&quot;</p><p>&nbsp;يُمكنك تأمين المزيد من المعلومات حول سلامة هذا الدواء من خلال الابلاغ عن الأعراض الجانبيّة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يُحفظ بعيدًا عن متناول أيدي ومرأى الأطفال.</p><p>لا تستخدم هذا الدواء بعد انتهاء تاريخ الصلاحيّة الوارد على العبوة أو على الحاوية بعد كلمة &quot;EXP&quot;. يُشير تاريخ إنتهاء الصلاحيّة إلى آخر يوم من الشهر المذكور.</p><p>يُحفظ في درجة حرارة أقل من ٣۰ درجة مئوية.</p><p>يُحفظ في العبوة الأصلية.</p><p>&nbsp;لا ينبغي التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. سوف تساعد هذه التدابير لحماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إزتيمايب هي المادة الفعالة. يحتوي كل قرص على 10 ملغم من إزتيمايب.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->المكوّنات الأخرى هي: أحادي هيدرات اللاكتوز، ميكروكريستالين سيلولوز، بوفيدون، صوديوم كروسكارميلوز، لوريل سلفات الصوديوم، ستيرات المغنزيوم</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            أقراص ازيترول لونها أبيض يميل إلى الصفرة ، على شكل كبسولات، مطبوع عليها من جهة واحدة رمز "414". 

أحجام العبوة:
7، أو 10، أو 14، أو 20، أو 28، أو 30، أو 50، أو 98، أو 100، أو 300 قرص في أشرطة لدفع الأقراص من خلال   فقّاعة أو وحدة  الجرعه الواحدة في  فقّاعة قابله للتقشير.
84 أو 90 قرصًا في أشرطة لدفع الأقراص من خلال  فقّاعة.
50، أو 100، أو300 قرصا على هيئة وحدة الجرعة الواحدة أشرطة لدفع الأقراص من خلال فقّاعة 
قد لا يتم تسويق جميع أحجام العبوات.


        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>الشركة المالكة لحقوق التسويق :</strong></p><p>ميرك شارب ودوم المحدودة،</p><p>طريق هيرتفورد، هوديسدون، هيرتفوردشاير</p><p>&nbsp;أي أن ١١ ٩ بي يو، المملكة المتحدة</p><p><strong><u>&nbsp;</u></strong></p><p><strong>الشركة الصانعة:</strong></p><p>أم أس دي إنترناشيونال جي أم بي أتش (فرع بورتو ريكو)،</p><p>عمليات لاس بيدراس، بريدكو حديقة صناعية،</p><p>طريق 183، لاس بيدراس، بورتو ريكو</p><p>بورتوريكو ٠٠٧٧١</p><p>&nbsp;</p><p><strong><u>&nbsp;</u></strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمّت آخر مراجعة لهذه النشرة في فبراير 2016
الاصدار رقم (2)

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ezetrol® 10 mg Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 10 mg of ezetimibe.  Excipient(s) with known effect:
Each tablet contains 55 mg of lactose monohydrate.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet.

White to off-white, capsule-shaped tablets, approximately 2.60 mm thick, debossed with “414” on one side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><!--[if !supportLists]--><strong>1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]--><strong>Therapeutic</strong><strong> </strong><strong>indications</strong></p><p><strong>&nbsp;</strong></p><p><u>Primary Hypercholesterolaemia</u></p><p>Ezetrol co-administered with an HMG-CoA reductase inhibitor (statin) is indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia who are not appropriately controlled with a statin alone.</p><p>&nbsp;</p><p>Ezetrol monotherapy is indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia in whom a statin is considered inappropriate or is not tolerated.</p><p>&nbsp;</p><p><strong><em>Prevention</em></strong><strong><em> </em></strong><strong><em>of Cardiovascular Events</em></strong></p><p>Ezetrol is indicated to reduce the risk of cardiovascular events (see section 5.1) in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS) when added to ongoing statin therapy or initiated concomitantly with a statin.</p><p>&nbsp;</p><p><u>Homozygous Familial Hypercholesterolaemia (HoFH)</u></p><p>Ezetrol co-administered with a statin, is indicated as adjunctive therapy to diet for use in patients with HoFH. Patients may also receive adjunctive treatments (e.g., LDL apheresis).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Homozygous Sitosterolaemia (Phytosterolaemia)</u></p><p>Ezetrol is indicated as adjunctive therapy to diet for use in patients with homozygous familial sitosterolaemia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>The patient should be on an appropriate lipid-lowering diet and should continue on this diet during treatment with Ezetrol.</p><p>&nbsp;</p><p>Route of administration is oral.&nbsp;&nbsp;&nbsp; The recommended dose is one Ezetrol 10 mg tablet daily. Ezetrol can be administered at any time of the day, with or without food.</p><p>&nbsp;</p><p>When Ezetrol is added to a statin, either the indicated usual initial dose of that particular statin or the already established higher statin dose should be continued. In this setting, the dosage instructions for that particular statin should be consulted.</p><p>&nbsp;</p><p><strong><em>Use</em></strong><strong><em> </em></strong><strong><em>in Patients with Coronary Heart Disease and ACS Event History</em></strong></p><p>For incremental cardiovascular event reduction in patients with coronary heart disease and ACS event history, Ezetrol 10 mg may be administered with a statin with proven cardiovascular benefit.</p><p>&nbsp;</p><p><em>Co-administration</em><em> </em><em>with bile acid sequestrants</em></p><p>Dosing of Ezetrol should occur either &sup3; 2 hours before or &sup3; 4 hours after administration of a bile acid sequestrant.</p><p>&nbsp;</p><p><em>Older</em><em> </em><em>people</em></p><p>No dosage adjustment is required for elderly patients (see section 5.2).</p><p>&nbsp;</p><p><em>Paediatric</em><em> </em><em>population</em></p><p>Initiation of treatment must be performed under review of a specialist.</p><p>&nbsp;</p><p>Children and adolescents &ge; 6 : The safety and efficacy of ezetimibe in children aged 6 to 17 years has not been established. Current available data are described in sections 4.4, 4.8, 5.1 and 5.2 but no recommendation on a posology can be made.</p><p>&nbsp;</p><p>When Ezetrol is administered with a statin, the dosage instructions for the statin in children should be consulted.</p><p>&nbsp;</p><p>Children &lt;6 years: The safety and efficacy of Ezetimibe in children aged &lt; 6 years has not been established. No data are available.</p><p>&nbsp;</p><p><em>Patients</em><em> </em><em>with hepatic impairment</em></p><p>&nbsp;</p><p>No dosage adjustment is required in patients with mild hepatic impairment (Child-Pugh score 5 to 6). Treatment with Ezetrol is not recommended in patients with moderate (Child-Pugh score 7 to 9) or severe (Child-Pugh score &gt; 9) liver dysfunction (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p><em>Patients</em><em> </em><em>with renal impairment</em></p><p>No dosage adjustment is required for renally impaired patients (see section 5.2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

When Ezetrol is co-administered with a statin, please  refer to the  SPC for that particular medicinal product.

Therapy with Ezetrol co-administered with a statin is contraindicated during pregnancy and lactation.

Ezetrol co-administered with a statin is contraindicated in patients with active liver disease or unexplained persistent elevations in serum transaminases.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>When Ezetrol is co-administered with a statin, please&nbsp; refer to the&nbsp; SPC for that particular medicinal product.</p><p>&nbsp;</p><p><u>Liver Enzymes</u></p><p>In controlled co-administration trials in patients receiving Ezetrol with a statin, consecutive transaminase elevations (&ge; 3 X the upper limit of normal [ULN]) have been observed. When Ezetrol is co-administered with a statin, liver function tests should be performed at initiation of therapy and according to the recommendations of the statin (see section 4.8.).</p><p>&nbsp;</p><p>In the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT), 18,144 patients with coronary heart disease and ACS event history were randomised to receive ezetimibe/simvastatin 10/40 mg daily (n=9067) or simvastatin 40 mg daily (n=9077). During a median follow-up of 6.0 years, &nbsp;the &nbsp;incidence &nbsp;of &nbsp;consecutive &nbsp;elevations &nbsp;of &nbsp;transaminases (&ge;3 X ULN) was 2.5% for ezetimibe/simvastatin and 2.3% for simvastatin. (See section 4.8)</p><p>&nbsp;</p><p>In a controlled clinical study in which over 9000 patients with chronic kidney disease were randomised to receive Ezetrol 10 mg combined with simvastatin 20 mg daily (n=4650) or placebo (n=4620) (median follow-up period of 4.9 years), the incidence of consecutive elevations of transaminases (&gt;3 X ULN) was 0.7% for Ezetrol combined with simvastatin and 0.6% for placebo (see section 4.8).</p><p>&nbsp;</p><p><u>Skeletal Muscle</u></p><p>&nbsp;</p><p>In post-marketing experience with Ezetrol, cases of myopathy and rhabdomyolysis have been reported. Most patients who developed rhabdomyolysis were taking a statin concomitantly with Ezetrol. However, rhabdomyolysis has been reported very rarely with Ezetrol monotherapy and very rarely with the addition of Ezetrol to other agents known to be associated with increased risk of rhabdomyolysis. If myopathy is suspected based on muscle symptoms or is confirmed by a creatine phosphokinase (CPK) level &gt;10 times the ULN, Ezetrol, any statin, and any of these other agents that the patient is taking concomitantly should be immediately discontinued. All patients starting therapy with Ezetrol should be advised of the risk of myopathy and told to report promptly any unexplained muscle pain, tenderness or weakness (see section 4.8).</p><p>&nbsp;</p><p>In IMPROVE-IT, 18,144 patients with coronary heart disease&nbsp; and ACS event history were randomised to receive ezetimibe/simvastatin 10/40 mg daily (n=9067) or simvastatin 40 mg daily (n=9077). During a median follow-up of 6.0 years, the incidence of myopathy was 0.2% for ezetimibe/simvastatin and 0.1% for simvastatin, where myopathy was defined as unexplained muscle weakness or pain with a serum CK &ge;10 times ULN or two consecutive observations of CK &ge;5 and &lt;10 times ULN. The incidence of rhabdomyolysis was 0.1% for ezetimibe/simvastatin and 0.2% for simvastatin, where rhabdomyolysis was defined as unexplained muscle weakness or pain with a serum CK &ge;10 times ULN with evidence of renal injury, &ge;5 times ULN and &lt;10 times ULN on two consecutive occasions with evidence of renal injury or CK &ge;10,000 IU/L without evidence of renal injury. (See section 4.8.)</p><p>&nbsp;</p><p>In a clinical trial in which over 9000 patients with chronic kidney disease were randomised to receive Ezetrol 10 mg combined with simvastatin 20 mg daily (n=4650) or placebo (n=4620) (median follow-up 4.9 years), the incidence of myopathy/rhabdomyolysis was 0.2% for Ezetrol combined with simvastatin and 0.1% for placebo (see section 4.8).</p><p>&nbsp;</p><p><u>Patients with hepatic impairment</u></p><p>Due to the unknown effects of the increased exposure to ezetimibe in patients with moderate or severe hepatic impairment, Ezetrol is not recommended (see section 5.2).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Efficacy and safety of Ezetrol in patients 6 to10 years of age with heterozygous familial or non- familial hypercholesterolemia have been evaluated in a 12-week placebo-controlled clinical trial. Effects of ezetimibe for treatment periods &gt; 12 weeks have not been studied in this age group (see sections 4.2, 4.8, 5.1 and 5.2).</p><p>&nbsp;</p><p>Ezetrol has not been studied in patients younger than 6 years of age (see sections 4.2 and 4.8.).</p><p>&nbsp;</p><p>Efficacy and safety of Ezetrol co-administered with simvastatin in patients 10 to 17 years of age with heterozygous familial hypercholesterolemia have been evaluated in a controlled clinical trial in adolescent boys (Tanner stage II or above) and in girls who were at least one year post- menarche.</p><p>&nbsp;</p><p>In this limited controlled study, there was generally no detectable effect on growth or sexual maturation in the adolescent boys or girls, or any effect on menstrual cycle length in girls.</p><p>&nbsp;</p><p>However, the effects of ezetimibe for a treatment period &gt; 33 weeks on growth and sexual maturation have not been studied (see sections 4.2 and 4.8).</p><p>&nbsp;</p><p>The safety and efficacy of Ezetrol co-administered with doses of simvastatin above 40mg daily have not been studied in paediatric patients 10 to 17 years of age.</p><p>&nbsp;</p><p>The safety and efficacy of Ezetrol co-administered with simvastatin have not been studied in paediatric patients &lt; 10 years of age (see sections 4.2 and 4.8).</p><p>&nbsp;</p><p>The long-term efficacy of therapy with Ezetrol in patients below 17 years of age to reduce morbidity and mortality in adulthood has not been studied.</p><p>&nbsp;</p><p><u>Fibrates</u></p><p>The safety and efficacy of Ezetrol administered with fibrates have not been established.</p><p>&nbsp;</p><p>If cholelithiasis is suspected in a patient receiving Ezetrol and fenofibrate, gallbladder investigations are indicated and this therapy should be discontinued (see sections 4.5 and 4.8).</p><p>&nbsp;</p><p><u>Ciclosporin</u></p><p>Caution should be exercised when initiating Ezetrol in the setting of ciclosporin. Ciclosporin concentrations should be monitored in patients receiving Ezetrol and ciclosporin (see section 4.5).</p><p>&nbsp;</p><p><u>Anticoagulants</u></p><p>If Ezetrol is added to warfarin, another coumarin anticoagulant, or fluindione, the International Normalised Ratio (INR) should be appropriately monitored (see section 4.5).</p><p>&nbsp;</p><p><u>Excipient</u></p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In preclinical studies, it has been shown that ezetimibe does not induce cytochrome P450 drug metabolising enzymes. No clinically significant pharmacokinetic interactions have been observed between ezetimibe and drugs known to be metabolised by cytochromes P450 1A2, 2D6, 2C8, 2C9, and 3A4, or N-acetyltransferase.</p><p>&nbsp;</p><p>In clinical interaction studies, ezetimibe had no effect on the pharmacokinetics of dapsone, dextromethorphan, digoxin, oral contraceptives (ethinyl estradiol and levonorgestrel), glipizide, tolbutamide, or midazolam during co-administration. Cimetidine, co-administered with ezetimibe, had no effect on the bioavailability of ezetimibe.</p><p>&nbsp;</p><p><u>Antacids</u></p><p>&nbsp;</p><p>Concomitant antacid administration decreased the rate of absorption of ezetimibe but had no effect on the bioavailability of ezetimibe. This decreased rate of absorption is not considered clinically significant.</p><p>&nbsp;</p><p><u>Cholestyramine</u></p><p>Concomitant cholestyramine administration decreased the mean area under the curve (AUC) of total ezetimibe (ezetimibe + ezetimibe glucuronide) approximately 55 %. The incremental low-density lipoprotein cholesterol (LDL-C) reduction due to adding Ezetrol to cholestyramine may be lessened by this interaction (see section 4.2).</p><p><u>Fibrates</u></p><p>In patients receiving fenofibrate and Ezetrol, physicians should be aware of the possible risk of cholelithiasis and gallbladder disease (see sections 4.4 and 4.8).</p><p>&nbsp;</p><p>If cholelithiasis is suspected in a patient receiving Ezetrol and fenofibrate, gallbladder investigations are indicated and this therapy should be discontinued (see section 4.8).</p><p>&nbsp;</p><p>Concomitant fenofibrate or gemfibrozil administration modestly increased total ezetimibe concentrations (approximately 1.5- and 1.7-fold respectively).</p><p>&nbsp;</p><p>Co-administration of Ezetrol with other fibrates has not been studied.</p><p>&nbsp;</p><p>Fibrates may increase cholesterol excretion into the bile, leading to cholelithiasis. In animal studies, ezetimibe sometimes increased cholesterol in the gallbladder bile but not in all species (see section 5.3). A lithogenic risk associated with the therapeutic use of Ezetrol cannot be ruled out.</p><p>&nbsp;</p><p><u>Statins</u></p><p>No clinically significant pharmacokinetic interactions were seen when ezetimibe was co- administered with atorvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, or rosuvastatin.</p><p>&nbsp;</p><p><u>Ciclosporin</u></p><p>In a study of eight post-renal transplant patients with creatinine clearance of &gt; 50 mL/min on a stable dose of ciclosporin, a single 10-mg dose of Ezetrol resulted in a 3.4-fold (range 2.3- to 7.9- fold) increase in the mean AUC for total ezetimibe compared to a healthy control population, receiving ezetimibe alone, from another study (n=17). In a different study, a renal transplant patient with severe renal impairment who was receiving ciclosporin and multiple other medications demonstrated a 12-fold greater exposure to total ezetimibe compared to concurrent controls receiving ezetimibe alone. In a two-period crossover study in twelve healthy subjects, daily administration of 20 mg ezetimibe for 8 days with a single 100-mg dose of ciclosporin on Day 7 resulted in a mean 15 % increase in ciclosporin AUC (range 10 % decrease to 51 % increase) compared to a single 100-mg dose of ciclosporin alone. A controlled study on the effect of co-administered ezetimibe on ciclosporin exposure in renal transplant patients has not been conducted. Caution should be exercised when initiating Ezetrol in the setting of ciclosporin. Ciclosporin concentrations should be monitored in patients receiving Ezetrol and ciclosporin (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Anticoagulants</u></p><p>Concomitant administration of ezetimibe (10 mg once daily) had no significant effect on bioavailability of warfarin and prothrombin time in a study of twelve healthy adult males. However, there have been post-marketing reports of increased International Normalised Ratio (INR) in patients who had Ezetrol added to warfarin or fluindione. If Ezetrol is added to warfarin, another coumarin anticoagulant, or fluindione, INR should be appropriately monitored (see section 4.4).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ezetrol co-administered with a statin is contraindicated during pregnancy and lactation (see section 4.3), please refer to the SPC for that particular statin.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>Ezetrol should be given to pregnant women only if clearly necessary. No clinical data are available on the use of Ezetrol during pregnancy. Animal studies on the use of ezetimibe in monotherapy have shown no evidence of direct or indirect harmful effects on pregnancy, embryofoetal development, birth or postnatal development (see section 5.3).</p><p>&nbsp;</p><p><u>Lactation</u></p><p>Ezetrol should not be used during lactation. Studies on rats have shown that ezetimibe is secreted into breast milk. It is not known if ezetimibe is secreted into human breast milk.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>No clinical trial data are available on the effects of ezetimibe on human fertility. Ezetimibe had no effect on the fertility of male or female rats (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been &nbsp;performed. However, when driving vehicles or operating machines, it should be taken into account that dizziness has been reported.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tabulated list of adverse reactions (clinical studies and post-marketing experience)</u></p><p>In clinical studies of up to 112 weeks duration, Ezetrol 10 mg daily was administered alone in 2396 patients, with a statin in 11,308 patients or with fenofibrate in 185 patients.&nbsp; Adverse reactions were usually mild and transient. The overall incidence of side effects was similar between Ezetrol and placebo. Similarly, the discontinuation rate due to adverse experiences was comparable between Ezetrol and placebo.</p><p>&nbsp;</p><p>&nbsp;</p><p>Ezetrol administered alone or co-administered with a statin:</p><p>&nbsp;</p><p>The following adverse reactions were observed in patients treated with Ezetrol (N=2396) and at a greater incidence than placebo (N=1159) or in patients treated with Ezetrol coadministered with a statin (N=11308) and at a greater incidence than statin administered alone (N=9361). Post- marketing Adverse reactions were derived from reports containing Ezetrol either administered alone or with a statin.</p><p>&nbsp;</p><p>Frequencies are defined as: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000) and not known (cannot be estimated from the available data)</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:15.65pt; vertical-align:top; width:6.15in" colspan="3"><p><strong>Ezetrol</strong><strong> </strong><strong>monotherapy</strong></p></td></tr><tr><td style="border-color:black; height:15.25pt; vertical-align:top; width:165.35pt"><p><strong>System</strong><strong> </strong><strong>organ</strong><strong> </strong><strong>class</strong></p></td><td style="height:15.25pt; vertical-align:top; width:191.05pt"><p><strong>Adverse</strong><strong> </strong><strong>reactions</strong></p></td><td style="height:15.25pt; vertical-align:top; width:1.2in"><p><strong>Frequency</strong></p></td></tr><tr><td style="border-color:black; height:57.1pt; vertical-align:top; width:165.35pt"><p>Investigations</p></td><td style="height:57.1pt; vertical-align:top; width:191.05pt"><p>ALT and/or AST increased; blood CPK increased; gamma- glutamyltransferase increased; liver function test abnormal</p></td><td style="height:57.1pt; vertical-align:top; width:1.2in"><p>Uncommon</p></td></tr><tr><td style="border-color:black; height:.4in; vertical-align:top; width:165.35pt"><p>Respiratory, Thoracic and Mediastinal Disorders</p></td><td style="height:.4in; vertical-align:top; width:191.05pt"><p>cough</p></td><td style="height:.4in; vertical-align:top; width:1.2in"><p>Uncommon</p></td></tr><tr><td style="border-color:black; height:14.65pt; vertical-align:top; width:165.35pt" rowspan="2"><p>Gastrointestinal Disorders</p></td><td style="height:14.65pt; vertical-align:top; width:191.05pt"><p>abdominal pain; diarrhoea; flatulence</p></td><td style="height:14.65pt; vertical-align:top; width:1.2in"><p>Common</p></td></tr><tr><td style="height:.4in; vertical-align:top; width:191.05pt"><p>dyspepsia; gastrooesophageal reflux disease; nausea</p></td><td style="height:.4in; vertical-align:top; width:1.2in"><p>Uncommon</p></td></tr><tr><td style="border-color:black; height:.4in; vertical-align:top; width:165.35pt"><p>Musculoskeletal And Connective Tissue Disorders</p></td><td style="height:.4in; vertical-align:top; width:191.05pt"><p>arthralgia; muscle spasms; neck pain</p></td><td style="height:.4in; vertical-align:top; width:1.2in"><p>Uncommon</p></td></tr><tr><td style="border-color:black; height:.4in; vertical-align:top; width:165.35pt"><p>Metabolism and Nutrition Disorders</p></td><td style="height:.4in; vertical-align:top; width:191.05pt"><p>decreased appetite</p></td><td style="height:.4in; vertical-align:top; width:1.2in"><p>Uncommon</p></td></tr><tr><td style="border-color:black; height:14.65pt; vertical-align:top; width:165.35pt"><p>Vascular Disorders</p></td><td style="height:14.65pt; vertical-align:top; width:191.05pt"><p>hot flush; hypertension</p></td><td style="height:14.65pt; vertical-align:top; width:1.2in"><p>Uncommon</p></td></tr><tr><td style="height:14.65pt; vertical-align:top; width:165.35pt" rowspan="2"><p>General Disorders And Administration Site Condition</p></td><td style="height:14.65pt; vertical-align:top; width:191.05pt"><p>fatigue</p></td><td style="height:14.65pt; vertical-align:top; width:1.2in"><p>Common</p></td></tr><tr><td style="height:15.2pt; vertical-align:top; width:191.05pt"><p>chest pain, pain</p></td><td style="height:15.2pt; vertical-align:top; width:1.2in"><p>Uncommon</p></td></tr><tr><td style="border-color:black; height:15.8pt; vertical-align:top; width:6.15in" colspan="3"><p><strong>Additional</strong><strong> </strong><strong>adverse</strong><strong> </strong><strong>reactions</strong><strong> </strong><strong>with Ezetrol co-administered with a statin</strong></p></td></tr><tr><td style="border-color:black; height:15.25pt; vertical-align:top; width:165.35pt"><p><strong>System</strong><strong> </strong><strong>organ</strong><strong> </strong><strong>class</strong></p></td><td style="height:15.25pt; vertical-align:top; width:191.05pt"><p><strong>Adverse</strong><strong> </strong><strong>reactions</strong></p></td><td style="height:15.25pt; vertical-align:top; width:1.2in"><p><strong>Frequency</strong></p></td></tr><tr><td style="border-color:black; height:14.65pt; vertical-align:top; width:165.35pt"><p>Investigations</p></td><td style="height:14.65pt; vertical-align:top; width:191.05pt"><p>ALT and/or AST increased</p></td><td style="height:14.65pt; vertical-align:top; width:1.2in"><p>Common</p></td></tr><tr><td style="border-color:black; height:14.65pt; vertical-align:top; width:165.35pt" rowspan="2"><p>Nervous System Disorders</p></td><td style="height:14.65pt; vertical-align:top; width:191.05pt"><p>headache</p></td><td style="height:14.65pt; vertical-align:top; width:1.2in"><p>Common</p></td></tr><tr><td style="height:14.65pt; vertical-align:top; width:191.05pt"><p>paraesthesia</p></td><td style="height:14.65pt; vertical-align:top; width:1.2in"><p>Uncommon</p></td></tr><tr><td style="border-color:black; height:14.65pt; vertical-align:top; width:165.35pt"><p>Gastrointestinal Disorders</p></td><td style="height:14.65pt; vertical-align:top; width:191.05pt"><p>dry mouth; gastritis</p></td><td style="height:14.65pt; vertical-align:top; width:1.2in"><p>Uncommon</p></td></tr><tr><td style="border-color:black; height:.4in; vertical-align:top; width:165.35pt"><p>Skin And Subcutaneous Tissue Disorders</p></td><td style="height:.4in; vertical-align:top; width:191.05pt"><p>pruritus; rash; urticaria</p></td><td style="height:.4in; vertical-align:top; width:1.2in"><p>Uncommon</p></td></tr><tr><td style="border-color:black; height:14.65pt; vertical-align:top; width:165.35pt" rowspan="2"><p>Musculoskeletal And Connective Tissue Disorders</p></td><td style="height:14.65pt; vertical-align:top; width:191.05pt"><p>myalgia</p></td><td style="height:14.65pt; vertical-align:top; width:1.2in"><p>Common</p></td></tr><tr><td style="height:.4in; vertical-align:top; width:191.05pt"><p>back pain; muscular weakness; pain</p><p>in extremity</p></td><td style="height:.4in; vertical-align:top; width:1.2in"><p>Uncommon</p></td></tr><tr><td style="border-color:black; height:.4in; vertical-align:top; width:165.35pt"><p>General Disorders And Administration Site Condition</p></td><td style="height:.4in; vertical-align:top; width:191.05pt"><p>asthenia; oedema peripheral</p></td><td style="height:.4in; vertical-align:top; width:1.2in"><p>Uncommon</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:15.7pt; vertical-align:top; width:6.15in" colspan="3"><p><strong>Post-marketing</strong><strong> </strong><strong>Experience</strong><strong> </strong><strong>(with</strong><strong> </strong><strong>or without a statin)</strong></p></td></tr><tr><td style="border-color:black; height:14.75pt; vertical-align:top; width:165.35pt"><p><strong>System</strong><strong> </strong><strong>organ</strong><strong> </strong><strong>class</strong></p></td><td style="height:14.75pt; vertical-align:top; width:191.05pt"><p><strong>Adverse</strong><strong> </strong><strong>reactions</strong></p></td><td style="height:14.75pt; vertical-align:top; width:1.2in"><p><strong>Frequency</strong></p></td></tr><tr><td style="border-color:black; height:.4in; vertical-align:top; width:165.35pt"><p>Blood and lymphatic system disorders</p></td><td style="height:.4in; vertical-align:top; width:191.05pt"><p>thrombocytopaenia</p></td><td style="height:.4in; vertical-align:top; width:1.2in"><p>Not known</p></td></tr><tr><td style="border-color:black; height:14.65pt; vertical-align:top; width:165.35pt"><p>Nervous system disorders:</p></td><td style="height:14.65pt; vertical-align:top; width:191.05pt"><p>dizziness; paraesthesia</p></td><td style="height:14.65pt; vertical-align:top; width:1.2in"><p>Not known</p></td></tr><tr><td style="border-color:black; height:.4in; vertical-align:top; width:165.35pt"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="height:.4in; vertical-align:top; width:191.05pt"><p>dyspnoea</p></td><td style="height:.4in; vertical-align:top; width:1.2in"><p>Not known</p></td></tr><tr><td style="border-color:black; height:14.65pt; vertical-align:top; width:165.35pt"><p>Gastrointestinal disorders</p></td><td style="height:14.65pt; vertical-align:top; width:191.05pt"><p>pancreatitis; constipation</p></td><td style="height:14.65pt; vertical-align:top; width:1.2in"><p>Not known</p></td></tr><tr><td style="border-color:black; height:.4in; vertical-align:top; width:165.35pt"><p>Skin and subcutaneous tissue disorders</p></td><td style="height:.4in; vertical-align:top; width:191.05pt"><p>erythema multiforme</p></td><td style="height:.4in; vertical-align:top; width:1.2in"><p>Not known</p></td></tr><tr><td style="border-color:black; height:.4in; vertical-align:top; width:165.35pt"><p>Musculoskeletal and connective tissue disorder</p></td><td style="height:.4in; vertical-align:top; width:191.05pt"><p>myalgia; myopathy/rhabdomyolysis</p><p>(see section 4.4)</p></td><td style="height:.4in; vertical-align:top; width:1.2in"><p>Not known</p></td></tr><tr><td style="border-color:black; height:.4in; vertical-align:top; width:165.35pt"><p>General disorders and administration site conditions</p></td><td style="height:.4in; vertical-align:top; width:191.05pt"><p>asthenia</p></td><td style="height:.4in; vertical-align:top; width:1.2in"><p>Not known</p></td></tr><tr><td style="border-color:black; height:42.95pt; vertical-align:top; width:165.35pt"><p>Immune system disorders</p></td><td style="height:42.95pt; vertical-align:top; width:191.05pt"><p>hypersensitivity, including rash, urticaria, anaphylaxis and</p><p>angio-oedema</p></td><td style="height:42.95pt; vertical-align:top; width:1.2in"><p>Not known</p></td></tr><tr><td style="border-color:black; height:14.65pt; vertical-align:top; width:165.35pt"><p>Hepatobiliary disorders</p></td><td style="height:14.65pt; vertical-align:top; width:191.05pt"><p>hepatitis; cholelithiasis; cholecystitis</p></td><td style="height:14.65pt; vertical-align:top; width:1.2in"><p>Not known</p></td></tr><tr><td style="border-color:black; height:14.65pt; vertical-align:top; width:165.35pt"><p>Psychiatric disorders</p></td><td style="height:14.65pt; vertical-align:top; width:191.05pt"><p>depression</p></td><td style="height:14.65pt; vertical-align:top; width:1.2in"><p>Not known</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Ezetrol co-administered with fenofibrate</u> Gastrointestinal disorders: abdominal pain (common)</p><p>&nbsp;</p><p>In a multicentre, double-blind, placebo-controlled, clinical study in patients with mixed hyperlipidaemia, 625 patients were treated for up to 12 weeks and 576 patients for up to 1 year. In this study, 172 patients treated with Ezetrol and fenofibrate completed 12 weeks of therapy, and 230 patients treated with Ezetrol and fenofibrate (including 109 who received Ezetrol alone for the first 12 weeks) completed 1 year of therapy. This study was not designed to compare treatment groups for infrequent events. Incidence rates (95 % CI) for clinically important elevations (&gt; 3 X ULN, consecutive) in serum transaminases were 4.5 % (1.9, 8.8) and 2.7 % (1.2, 5.4) for fenofibrate monotherapy and Ezetrol co-administered with fenofibrate, respectively, adjusted for treatment exposure. Corresponding incidence rates for cholecystectomy were 0.6 % (0.0, 3.1) and 1.7 % (0.6, 4.0) for fenofibrate monotherapy and Ezetrol co-administered with fenofibrate, respectively (see sections 4.4 and 4.5).</p><p>&nbsp;</p><p><u>Paediatric (6 to 17 years of age) Patients</u></p><p>In a study involving paediatric (6 to 10 years of age) patients with heterozygous familial or non-familial hypercholesterolaemia (n=138), elevations of ALT and/or AST (&ge; 3X ULN, consecutive) were observed in 1.1% (1 patient) of the ezetimibe patients compared to 0% in the placebo group. There were no elevations of CPK (&ge; 10X ULN). No cases of myopathy were reported.</p><p>&nbsp;</p><p>In a separate study involving adolescent (10 to 17 years of age) patients with heterozygous familial hypercholesterolaemia (n=248), elevations of ALT and/or AST (&ge; 3X ULN, consecutive) were observed in 3% (4 patients) of the ezetimibe/simvastatin patients compared to 2% (2</p><p>&nbsp;</p><p>patients) in the simvastatin monotherapy group; these figures were respectively 2% (2 patients) and 0% for elevation of CPK (&ge; 10X ULN). No cases of myopathy were reported.</p><p>These trials were not suited for comparison of rare adverse drug reactions. <u>Patients with Coronary Heart Disease and ACS Event History</u></p><p>In &nbsp;the &nbsp;IMPROVE-IT &nbsp;study (see &nbsp;section &nbsp;5.1), &nbsp;involving &nbsp;18,144 &nbsp;patients &nbsp;treated &nbsp;with &nbsp;either</p><p>ezetimibe/simvastatin 10/40 mg (n=9067; of whom 6% were uptitrated to ezetimibe/simvastatin 10/80 mg) or simvastatin 40 mg (n=9077; of whom 27% were uptitrated to simvastatin 80 mg), the safety profiles were similar during a median follow-up period of 6.0 years<em>.</em><em> </em>Discontinuation rates due to adverse experiences were 10.6% for patients treated with ezetimibe/simvastatin and 10.1% for patients treated with simvastatin. The incidence of myopathy was 0.2% for ezetimibe/simvastatin and 0.1% for simvastatin, where myopathy was defined as unexplained muscle weakness or pain with a serum CK &ge;10 times ULN or two consecutive observations of CK &ge;5 and &lt;10 times ULN. The incidence of rhabdomyolysis was 0.1% for ezetimibe/simvastatin and 0.2% for simvastatin, where rhabdomyolysis was defined as unexplained muscle weakness or pain with a serum CK &ge;10 times ULN with evidence of renal injury, &ge;5 times ULN and &lt;10 times ULN on two consecutive occasions with evidence of renal injury or CK &ge;10,000 IU/L without evidence of renal injury. The incidence of consecutive elevations of transaminases (&ge;3 X ULN) was 2.5% for ezetimibe/simvastatin and 2.3% for simvastatin (see section 4.4.).&nbsp; Gallbladder-related adverse effects were reported in 3.1% vs 3.5% of patients allocated to ezetimibe/simvastatin and simvastatin, respectively. The incidence of cholecystectomy hospitalisations was 1.5% in both treatment groups. Cancer (defined as any new malignancy) was diagnosed during the trial in 9.4% vs 9.5%, respectively.</p><p>&nbsp;</p><p><u>Patients with Chronic Kidney Disease</u></p><p>In the Study of Heart and Renal Protection (SHARP) (see section 5.1), involving over 9000 patients treated with a fixed dose combination of Ezetrol 10 mg with simvastatin 20 mg daily (n=4650) or placebo (n=4620), the safety profiles were comparable during a median follow-up period of 4.9 years. In this trial, only serious adverse events and discontinuations due to any adverse events were recorded. Discontinuation rates due to adverse events were comparable (10.4% in patients treated with Ezetrol combined with simvastatin, 9.8% in patients treated with placebo). The incidence of myopathy/rhabdomyolysis was 0.2% in patients treated with Ezetrol combined with simvastatin and 0.1% in patients treated with placebo. Consecutive elevations of transaminases (&gt; 3X ULN) occurred in 0.7% of patients treated with Ezetrol combined with simvastatin compared with 0.6% of patients treated with placebo (see section 4.4.). In this trial, there were no statistically significant increases in the incidence of pre-specified adverse events, including cancer (9.4% for Ezetrol combined with simvastatin, 9.5% for placebo), hepatitis, cholecystectomy or complications of gallstones or pancreatitis.</p><p>&nbsp;</p><p><u>Laboratory values:</u></p><p>In controlled clinical monotherapy trials, the incidence of clinically important elevations in serum transaminases (ALT and/or AST &sup3; 3 X ULN, consecutive) was similar between Ezetrol (0.5 %) and placebo (0.3 %). In co-administration trials, the incidence was 1.3 % for patients treated with Ezetrol co-administered with a statin and 0.4 % for patients treated with a statin</p><p>&nbsp;</p><p>alone. These elevations were generally asymptomatic, not associated with cholestasis, and returned to baseline after discontinuation of therapy or with continued treatment (see section 4.4.).</p><p>&nbsp;</p><p>In clinical trials, CPK &gt;10 X ULN was reported for 4 of 1674 (0.2 %) patients administered Ezetrol alone vs 1 of 786 (0.1 %) patients administered placebo, and for 1 of 917 (0.1 %) patients co-administered Ezetrol and a statin vs 4 of 929 (0.4 %) patients administered a statin alone. There was no excess of myopathy or rhabdomyolysis associated with Ezetrol compared with the relevant control arm (placebo or statin alone) (see section 4.4).</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><p><strong>&nbsp; To report any side effect(s):</strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Saudi Arabia: </u></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-20382222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Other GCC States: </u></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical studies, &nbsp;administration&nbsp; of ezetimibe, 50 mg/day to 15 healthy subjects for up to 14 days, or 40 mg/day to 18 patients with primary hypercholesterolaemia for up to 56 days, was generally well tolerated. In animals, no toxicity &nbsp;was &nbsp;observed &nbsp;after &nbsp;single &nbsp;oral &nbsp;doses &nbsp;of 5000 mg/kg of ezetimibe in rats and mice and 3000 mg/kg in dogs.</p><p>&nbsp;</p><p>A few cases of overdosage with Ezetrol have been reported; most have not been associated with adverse experiences. Reported adverse experiences have not been serious. In the event of an overdose, symptomatic and supportive measures should be employed.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other lipid modifying agents, ATC code: C10A X09</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Ezetrol is in a new class of lipid-lowering compounds that selectively inhibit the intestinal absorption of cholesterol and related plant sterols. Ezetrol is orally active and has a mechanism of action that differs from other classes of cholesterol-reducing compounds (e.g., statins, bile acid sequestrants [resins], fibric acid derivatives, and plant stanols). The molecular target of ezetimibe is the&nbsp; sterol transporter, Niemann-Pick C1-Like&nbsp; 1 (NPC1L1), which is responsible&nbsp; for the intestinal uptake of cholesterol and phytosterols.</p><p>&nbsp;</p><p>Ezetimibe localises at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver; statins reduce &nbsp;cholesterol &nbsp;synthesis &nbsp;in &nbsp;the &nbsp;liver &nbsp;and &nbsp;together &nbsp;these &nbsp;distinct &nbsp;mechanisms &nbsp;provide</p><p>complementary cholesterol reduction. In a 2-week clinical study in 18 hypercholesterolaemic patients, Ezetrol inhibited intestinal cholesterol absorption by 54 %, compared with placebo.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>A series of preclinical studies was performed to determine the selectivity of ezetimibe for inhibiting cholesterol absorption. Ezetimibe inhibited the absorption of [14C]-cholesterol with no effect on the absorption of triglycerides, fatty acids, bile acids, progesterone, ethinyl estradiol, or fat soluble vitamins A and D.</p><p>&nbsp;</p><p>Epidemiologic studies have established that cardiovascular morbidity and mortality vary directly with the level of total-C and LDL-C and inversely with the level of HDL-C.</p><p>Administration of Ezetrol with a statin is effective in reducing the risk of cardiovascular events in patients with coronary heart disease and ACS event history.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>In controlled clinical studies, Ezetrol either as monotherapy or co-administered with a statin significantly reduced total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG) and increased high-density lipoprotein cholesterol (HDL-C) in patients with hypercholesterolaemia.</p><p>&nbsp;</p><p><em>Primary</em><em> </em><em>Hypercholesterolaemia</em></p><p>In a double-blind, placebo-controlled, 8-week study, 769 patients with hypercholesterolaemia already receiving statin monotherapy and not at National Cholesterol Education Program (NCEP) LDL-C goal (2.6 to 4.1 mmol/l [100 to 160 mg/dl], depending on baseline characteristics) were randomised to receive either Ezetrol 10 mg or placebo in addition to their on-going statin therapy.</p><p>&nbsp;</p><p>Among statin-treated patients not at LDL-C goal at baseline (~82 %), significantly more patients randomised to Ezetrol achieved their LDL-C goal at study endpoint compared to patients randomised to placebo, 72 % and 19 %, respectively. The corresponding LDL-C reductions were significantly different (25 % and 4 % for Ezetrol versus placebo, respectively). In addition, Ezetrol, added to on-going statin therapy, significantly decreased total-C, Apo B, TG and increased HDL-C, compared with placebo. Ezetrol or placebo added to statin therapy reduced median C-reactive protein by 10 % or 0 % from baseline, respectively.</p><p>&nbsp;</p><p>In two, double-blind, randomised placebo-controlled, 12-week studies in 1719 patients with primary hypercholesterolaemia, Ezetrol 10 mg significantly lowered total-C (13 %), LDL-C (19</p><p>%), Apo B (14 %), and TG (8 %) and increased HDL-C (3 %) compared to placebo. In addition, Ezetrol had no effect on the plasma concentrations of fat-soluble vitamins A, D, and E, no effect on prothrombin time, and, like other lipid lowering agents, did not impair adrenocortical steroid hormone production.</p><p>&nbsp;</p><p>In a multicenter, double-blind, controlled clinical study (ENHANCE), 720 patients with heterozygous familial hypercholesterolemia were randomised to receive ezetimibe 10 mg in combination with simvastatin 80 mg (n=357) or simvastatin 80 mg (n=363) for 2 years. The</p><p>primary objective of the study was to investigate the effect of the ezetimibe/simvastatin combination therapy on carotid artery intima-media thickness (IMT) compared to simvastatin monotherapy. The impact of this surrogate marker on cardiovascular morbidity and mortality is still not demonstrated.</p><p>&nbsp;</p><p>The primary endpoint, the change in the mean IMT of all six carotid segments, did not differ significantly (p= 0.29) between the two treatment groups as measured by B-mode ultrasound. With ezetimibe 10 mg in combination with simvastatin 80 mg or simvastatin 80 mg alone, intima-medial thickening increased by 0.0111 mm and 0.0058 mm, respectively, over the study&rsquo;s 2 year duration (baseline mean carotid IMT 0.68 mm and 0.69 mm respectively.</p><p>&nbsp;</p><p>Ezetimibe 10 mg in combination with simvastatin 80 mg lowered LDL-C, total-C, Apo B, and TG significantly more than simvastatin 80 mg. The percent increase in HDL-C was similar for the two treatment groups. The adverse reactions reported for ezetimibe 10 mg in combination with simvastatin 80 mg were consistent with its known safety profile.</p><p>&nbsp;</p><p><em>Paediatric</em><em> </em><em>population</em></p><p>In a multicentre, double-blind, controlled study, 138 patients (59 boys and 79 girls), 6 to 10 years of age (mean age 8.3 years) with heterozygous familial or non-familial hypercholesterolaemia (HeFH) with baseline LDL-C levels between 3.74 and 9.92 mmol/l were randomised to either Ezetrol 10 mg or placebo for 12 weeks.</p><p>&nbsp;</p><p>At week 12, Ezetrol significantly reduced total-C (-21% vs. 0%), LDL-C (-28% vs. -1%), Apo-B (-22% vs. -1%), and non-HDL-C (-26% vs. 0%) compared to placebo. Results for the two treatment groups were similar for TG and HDL-C (-6% vs. +8%, and +2% vs. +1%, respectively).</p><p>&nbsp;</p><p>In a&nbsp; multicentre, double-blind, controlled study, 142 boys (Tanner stage II and above) and 106 postmenarchal girls, 10 to 17 years of age (mean age 14.2 years) with heterozygous familial hypercholesterolaemia (HeFH) with baseline LDL-C levels between 4.1 and 10.4 mmol/l were randomised to either Ezetrol 10 mg co-administered with simvastatin (10, 20 or 40 mg) or simvastatin (10, 20 or 40 mg) alone for 6 weeks, co-administered Ezetrol and 40 mg simvastatin or 40 mg simvastatin alone for the next 27 weeks, and open-label co-administered Ezetrol and simvastatin (10 mg, 20 mg, or 40 mg) for 20 weeks thereafter.</p><p>&nbsp;</p><p>At Week 6, Ezetrol co-administered with simvastatin (all doses) significantly reduced total-C (38 % vs 26 %), LDL-C (49 % vs 34 %), Apo B (39 % vs 27 %), and non-HDL-C (47 % vs</p><p>33 %) compared to simvastatin (all doses) alone. Results for the two treatment groups were similar for TG and HDL-C (-17 % vs -12 % and +7 % vs +6 %, respectively). At Week 33, results were consistent with those at Week 6 and significantly more patients receiving Ezetrol and 40 mg simvastatin (62 %) attained the NCEP AAP ideal goal (&lt; 2.8 mmol/L [110 mg/dL]) for LDL-C compared to those receiving 40 mg simvastatin (25 %). At Week 53, the end of the open label extension, the effects on lipid parameters were maintained.</p><p>The safety and efficacy of Ezetrol co-administered with doses of simvastatin above 40 mg daily have not been studied in paediatric patients 10 to 17 years of age. The safety and efficacy of Ezetrol co-administered with simvastatin have not been studied in paediatric patients &lt; 10 years of age.</p><p>&nbsp;</p><p>The long-term efficacy of therapy with Ezetrol in patients below 17 years of age to reduce morbidity and mortality in adulthood has not been studied.</p><p>&nbsp;</p><p><em>Prevention</em><em> </em><em>of Cardiovascular Events</em></p><p>The IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) was a multicenter, randomised, double-blind, active-control study of 18,144 patients enrolled within 10 days of hospitalisation for acute coronary syndrome (ACS; either acute myocardial infarction [MI] or unstable angina [UA]). Patients had an LDL-C &le;125 mg/dL (&le;3.2 mmol/L) at the time of presentation with ACS if they had not been &nbsp;taking lipid-lowering&nbsp; therapy, &nbsp;or &nbsp;&le;100 mg/dL (&le;2.6 mmol/L) if they had been receiving lipid-lowering therapy. All patients were randomised in a 1:1 ratio to receive either ezetimibe/simvastatin 10/40 mg (n=9067) or simvastatin 40 mg (n=9077) and followed for a median of 6.0 years.</p><p>&nbsp;</p><p>Patients had a mean age of 63.6 years; 76% were male, 84% were Caucasian, and 27% were diabetic. The average LDL-C value &nbsp;at &nbsp;the &nbsp;time &nbsp;of &nbsp;study &nbsp;qualifying &nbsp;event &nbsp;was &nbsp;80 mg/dL (2.1 mmol/L) for those on lipid-lowering therapy (n=6390) and 101 mg/dL (2.6 mmol/L) for those not on previous lipid-lowering therapy (n=11594). Prior to the hospitalisation for the qualifying ACS event, 34% of the patients were on statin therapy. At one year, the average LDL- C for patients continuing on therapy was 53.2 mg/dL (1.4 mmol/L) for the ezetimibe/simvastatin group and 69.9 mg/dL (1.8 mmol/L) for the simvastatin monotherapy group. Lipid values were generally obtained for patients who remained on study therapy.</p><p>&nbsp;</p><p>The primary endpoint was a composite consisting of cardiovascular death, major coronary events (MCE; defined as non-fatal myocardial infarction, documented unstable angina that required hospitalisation, or any coronary revascularisation procedure occurring at least 30 days after randomised treatment assignment) and non-fatal stroke. The study demonstrated that treatment with ezetimibe when added to simvastatin provided incremental benefit in reducing the primary composite endpoint of cardiovascular death, MCE, and non-fatal stroke compared with simvastatin alone (relative risk reduction of 6.4%, p=0.016). The primary endpoint occurred in 2572 of 9067 patients (7-year Kaplan-Meier [KM] rate 32.72%) in the ezetimibe/simvastatin group and 2742 of 9077 patients (7-year KM rate 34.67%) in the simvastatin alone group. (See Figure 1 and Table 1.) This incremental benefit is expected to be similar with coadministration of other statins shown to be effective in reducing the risk of cardiovascular events. Total mortality was unchanged in this high risk group (see Table 1).</p><p>&nbsp;</p><p>There was an overall benefit for all strokes; however there was a small non-significant increase in haemorrhagic stroke in the ezetimibe-simvastatin group compared with simvastatin alone (see Table 1). The risk of haemorrhagic stroke for ezetimibe coadministered with higher potency statins in long-term outcome studies has not been evaluated.</p><p>&nbsp;</p><p>The treatment effect of ezetimibe/simvastatin was generally consistent with the overall results across many subgroups, including sex, age, race, medical history of diabetes mellitus, baseline lipid levels, prior statin therapy, prior stroke, and hypertension.</p><p>&nbsp;</p><p>Figure 1: Effect of Ezetimibe/Simvastatin on the Primary Composite Endpoint of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="image1.png" o:spid="_x0000_i1025" type="#_x0000_t75"
 alt="þÿ" style='width:5in;height:4in;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title="þÿ"/>
</v:shape><![endif]--><!--[if !vml]--><img width="480" height="384" alt="þÿ" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /><!--[endif]--></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
 margin-left:67.8pt;margin-top:115.55pt;width:476.3pt;height:591.5pt;z-index:1048;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:page'
 filled="f" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page" anchory="page"/>
</v:shape><![endif]--><!--[if !vml]--></p><table align="left" cellspacing="0" cellpadding="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td style="vertical-align:top"><!--[endif]--><!--[if !mso]--><table style="width:100%" cellspacing="0" cellpadding="0"><tbody><tr><td><!--[endif]--><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="height:42.3pt; vertical-align:top; width:140.95pt"><p><strong><u>Outcome</u></strong></p></td><td style="height:42.3pt; vertical-align:top; width:127.75pt" colspan="2"><p><strong>Ezetimibe/Simvastatin</strong><strong> </strong><strong>10/40 mg</strong>a&nbsp;<strong>(N=9067)</strong></p></td><td style="height:42.3pt; vertical-align:top; width:98.5pt"><p>&nbsp;</p></td><td style="height:42.3pt; vertical-align:top; width:50.05pt"><p><strong>Hazard</strong><strong> </strong><strong>Ratio</strong><strong> </strong><strong>(95%</strong><strong> </strong><strong>CI</strong></p></td><td style="height:42.3pt; vertical-align:top; width:18.3pt"><p>&nbsp;</p></td><td style="height:42.3pt; vertical-align:top; width:40.8pt"><p>&nbsp;</p></td></tr><tr><td style="height:31.15pt; vertical-align:top; width:140.95pt"><p>&nbsp;</p></td><td style="height:31.15pt; vertical-align:top; width:56.05pt"><p>n</p></td><td style="height:31.15pt; vertical-align:top; width:71.7pt"><p>K-M % c</p></td><td style="height:31.15pt; vertical-align:top; width:98.5pt"><p>n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; K-M %</p><p>c</p></td><td style="height:31.15pt; vertical-align:top; width:50.05pt"><p>&nbsp;</p></td><td style="height:31.15pt; vertical-align:top; width:18.3pt"><p>&nbsp;</p></td><td style="height:31.15pt; vertical-align:top; width:40.8pt"><p>&nbsp;</p></td></tr><tr><td style="height:19.7pt; vertical-align:top; width:476.3pt" colspan="7"><p><strong>Primary</strong><strong> </strong><strong>Composite</strong><strong> </strong><strong>Efficacy Endpoint</strong></p></td></tr><tr><td style="height:48.95pt; vertical-align:top; width:140.95pt"><p>(CV death, Major Coronary Events and non-fatal stroke)</p></td><td style="height:48.95pt; vertical-align:top; width:56.05pt"><p><strong>&nbsp;</strong></p><p>2572</p></td><td style="height:48.95pt; vertical-align:top; width:71.7pt"><p><strong>&nbsp;</strong></p><p>32.72%</p></td><td style="height:48.95pt; vertical-align:top; width:166.8pt" colspan="3"><p>2742&nbsp;&nbsp;&nbsp;&nbsp; 34.67%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.936 (0.887,</p><p>0.988)</p></td><td style="height:48.95pt; vertical-align:top; width:40.8pt"><p><strong>&nbsp;</strong></p><p>0.016</p></td></tr><tr><td style="height:19.55pt; vertical-align:top; width:476.3pt" colspan="7"><p><strong>Secondary</strong><strong> </strong><strong>Composite</strong><strong> </strong><strong>Efficacy Endpoints</strong></p></td></tr><tr><td style="height:61.9pt; vertical-align:top; width:140.95pt"><p>CHD death, nonfatal MI, urgent coronary revascularisation after 30 days</p></td><td style="height:61.9pt; vertical-align:top; width:56.05pt"><p><strong>&nbsp;</strong></p><p>1322</p></td><td style="height:61.9pt; vertical-align:top; width:71.7pt"><p><strong>&nbsp;</strong></p><p>17.52%</p></td><td style="height:61.9pt; vertical-align:top; width:166.8pt" colspan="3"><p>1448&nbsp;&nbsp;&nbsp;&nbsp; 18.88%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.912 (0.847,</p><p>0.983)</p></td><td style="height:61.9pt; vertical-align:top; width:40.8pt"><p><strong>&nbsp;</strong></p><p>0.016</p></td></tr><tr><td style="height:33.6pt; vertical-align:top; width:140.95pt"><p>MCE, non-fatal stroke, death (all causes)</p></td><td style="height:33.6pt; vertical-align:top; width:56.05pt"><p>3089</p></td><td style="height:33.6pt; vertical-align:top; width:71.7pt"><p>38.65%</p></td><td style="height:33.6pt; vertical-align:top; width:166.8pt" colspan="3"><p>3246&nbsp;&nbsp;&nbsp;&nbsp; 40.25%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.948 (0.903,</p><p>0.996)</p></td><td style="height:33.6pt; vertical-align:top; width:40.8pt"><p>0.035</p></td></tr><tr><td style="height:77.9pt; vertical-align:top; width:140.95pt"><p>CV death, non-fatal MI, unstable angina requiring hospitalisation, any revascularisation, non- fatal stroke</p></td><td style="height:77.9pt; vertical-align:top; width:56.05pt"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>2716</p></td><td style="height:77.9pt; vertical-align:top; width:71.7pt"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>34.49%</p></td><td style="height:77.9pt; vertical-align:top; width:166.8pt" colspan="3"><p><strong>&nbsp;</strong></p><p>2869&nbsp;&nbsp;&nbsp;&nbsp; 36.20%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.945 (0.897,</p><p>0.996)</p></td><td style="height:77.9pt; vertical-align:top; width:40.8pt"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>0.035</p></td></tr><tr><td style="height:33.95pt; vertical-align:top; width:476.3pt" colspan="7"><p><strong>Components</strong><strong> </strong><strong>of Primary Composite Endpoint and Select Efficacy Endpoints </strong>(first occurrences of specified event at any time)</p></td></tr><tr><td style="height:33.6pt; vertical-align:top; width:140.95pt"><p>Cardiovascular death</p></td><td style="height:33.6pt; vertical-align:top; width:56.05pt"><p>537</p></td><td style="height:33.6pt; vertical-align:top; width:71.7pt"><p>6.89%</p></td><td style="height:33.6pt; vertical-align:top; width:166.8pt" colspan="3"><p>538&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6.84%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.000 (0.887,</p><p>1.127)</p></td><td style="height:33.6pt; vertical-align:top; width:40.8pt"><p>0.997</p></td></tr><tr><td style="height:19.45pt; vertical-align:top; width:476.3pt" colspan="7"><p>Major Coronary Event:</p></td></tr><tr><td style="height:33.6pt; vertical-align:top; width:140.95pt"><p>Non-fatal MI</p></td><td style="height:33.6pt; vertical-align:top; width:56.05pt"><p>945</p></td><td style="height:33.6pt; vertical-align:top; width:71.7pt"><p>12.77%</p></td><td style="height:33.6pt; vertical-align:top; width:166.8pt" colspan="3"><p>1083&nbsp;&nbsp;&nbsp;&nbsp; 14.41%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.871 (0.798,</p><p>0.950)</p></td><td style="height:33.6pt; vertical-align:top; width:40.8pt"><p>0.002</p></td></tr><tr><td style="height:33.6pt; vertical-align:top; width:140.95pt"><p>Unstable angina</p><p>requiring hospitalisation</p></td><td style="height:33.6pt; vertical-align:top; width:56.05pt"><p>156</p></td><td style="height:33.6pt; vertical-align:top; width:71.7pt"><p>2.06%</p></td><td style="height:33.6pt; vertical-align:top; width:166.8pt" colspan="3"><p>148&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.92%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.059 (0.846,</p><p>1.326)</p></td><td style="height:33.6pt; vertical-align:top; width:40.8pt"><p>0.618</p></td></tr><tr><td style="height:47.75pt; vertical-align:top; width:140.95pt"><p>Coronary revascularisation after 30 days</p></td><td style="height:47.75pt; vertical-align:top; width:56.05pt"><p><strong>&nbsp;</strong></p><p>1690</p></td><td style="height:47.75pt; vertical-align:top; width:71.7pt"><p><strong>&nbsp;</strong></p><p>21.84%</p></td><td style="height:47.75pt; vertical-align:top; width:166.8pt" colspan="3"><p>1793&nbsp;&nbsp;&nbsp;&nbsp; 23.36%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.947 (0.886,</p><p>1.012)</p></td><td style="height:47.75pt; vertical-align:top; width:40.8pt"><p><strong>&nbsp;</strong></p><p>0.107</p></td></tr><tr><td style="height:33.6pt; vertical-align:top; width:140.95pt"><p>Non-fatal stroke</p></td><td style="height:33.6pt; vertical-align:top; width:56.05pt"><p>245</p></td><td style="height:33.6pt; vertical-align:top; width:71.7pt"><p>3.49%</p></td><td style="height:33.6pt; vertical-align:top; width:166.8pt" colspan="3"><p>305&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.24%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.802 (0.678,</p><p>0.949)</p></td><td style="height:33.6pt; vertical-align:top; width:40.8pt"><p>0.010</p></td></tr><tr><td style="height:19.45pt; vertical-align:top; width:140.95pt"><p>All MI (fatal and non-</p></td><td style="height:19.45pt; vertical-align:top; width:56.05pt"><p>977</p></td><td style="height:19.45pt; vertical-align:top; width:71.7pt"><p>13.13%</p></td><td style="height:19.45pt; vertical-align:top; width:166.8pt" colspan="3"><p>1118&nbsp;&nbsp;&nbsp;&nbsp; 14.82%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.872 (0.800,</p></td><td style="height:19.45pt; vertical-align:top; width:40.8pt"><p>0.002</p></td></tr></tbody></table><p>&nbsp;</p><!--[if !mso]--></td></tr></tbody></table><!--[endif]--><!--[if !mso & !vml]-->&nbsp;<!--[endif]--><!--[if !vml]--></td></tr></tbody></table><p><!--[endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Table 1</p><p>Major Cardiovascular Events by Treatment Group in All Randomised Patients in IMPROVE-IT</p><p>p- value</p><p><strong>)</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:shape id="_x0000_s1027"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:67.8pt;margin-top:-148.15pt;width:476.3pt;height:154.7pt;
 z-index:1072;mso-position-horizontal-relative:page' filled="f" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><!--[if !vml]--></p><table cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><!--[endif]--><!--[if !mso]--><table style="width:100%" cellspacing="0" cellpadding="0"><tbody><tr><td><!--[endif]--><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="height:17.05pt; vertical-align:top; width:476.3pt" colspan="7"><p>fatal)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.950)</p></td></tr><tr><td style="height:33.6pt; vertical-align:top; width:144.9pt"><p>All stroke (fatal and non- fatal)</p></td><td style="height:33.6pt; vertical-align:top; width:53.5pt"><p>296</p></td><td style="height:33.6pt; vertical-align:top; width:65.3pt"><p>4.16%</p></td><td style="height:33.6pt; vertical-align:top; width:43.05pt"><p>345</p></td><td style="height:33.6pt; vertical-align:top; width:50.8pt"><p>4.77%</p></td><td style="height:33.6pt; vertical-align:top; width:78.0pt"><p>0.857 (0.734,</p><p>1.001)</p></td><td style="height:33.6pt; vertical-align:top; width:40.75pt"><p>0.052</p></td></tr><tr><td style="height:33.6pt; vertical-align:top; width:144.9pt"><p>Non-hemorrhagic stroke</p><p>d</p></td><td style="height:33.6pt; vertical-align:top; width:53.5pt"><p>242</p></td><td style="height:33.6pt; vertical-align:top; width:65.3pt"><p>3.48%</p></td><td style="height:33.6pt; vertical-align:top; width:43.05pt"><p>305</p></td><td style="height:33.6pt; vertical-align:top; width:50.8pt"><p>4.23%</p></td><td style="height:33.6pt; vertical-align:top; width:78.0pt"><p>0.793 (0.670,</p><p>0.939)</p></td><td style="height:33.6pt; vertical-align:top; width:40.75pt"><p>0.007</p></td></tr><tr><td style="height:33.6pt; vertical-align:top; width:144.9pt"><p>Hemorrhagic stroke</p></td><td style="height:33.6pt; vertical-align:top; width:53.5pt"><p>59</p></td><td style="height:33.6pt; vertical-align:top; width:65.3pt"><p>0.77%</p></td><td style="height:33.6pt; vertical-align:top; width:43.05pt"><p>43</p></td><td style="height:33.6pt; vertical-align:top; width:50.8pt"><p>0.59%</p></td><td style="height:33.6pt; vertical-align:top; width:78.0pt"><p>1.377 (0.930,</p><p>2.040)</p></td><td style="height:33.6pt; vertical-align:top; width:40.75pt"><p>0.110</p></td></tr><tr><td style="height:35.4pt; vertical-align:top; width:144.9pt"><p>Death from any cause</p></td><td style="height:35.4pt; vertical-align:top; width:53.5pt"><p>1215</p></td><td style="height:35.4pt; vertical-align:top; width:65.3pt"><p>15.36%</p></td><td style="height:35.4pt; vertical-align:top; width:43.05pt"><p>1231</p></td><td style="height:35.4pt; vertical-align:top; width:50.8pt"><p>15.28%</p></td><td style="height:35.4pt; vertical-align:top; width:78.0pt"><p>0.989 (0.914,</p><p>1.070)</p></td><td style="height:35.4pt; vertical-align:top; width:40.75pt"><p>0.782</p></td></tr></tbody></table><p>&nbsp;</p><!--[if !mso]--></td></tr></tbody></table><!--[endif]--><!--[if !mso & !vml]-->&nbsp;<!--[endif]--><!--[if !vml]--></td></tr></tbody></table><p><!--[endif]--></p><p>a&nbsp; &nbsp;6% were uptitrated to ezetimibe/simvastatin 10/80 mg.</p><p>&nbsp;</p><p>b&nbsp; &nbsp;27% were uptitrated to simvastatin 80 mg.</p><p>c&nbsp; &nbsp;Kaplan-Meier estimate at 7 years.</p><p>d&nbsp; &nbsp;includes ischemic stroke or stroke of undetermined type.</p><p>&nbsp;</p><p><em>Prevention</em><em> </em><em>of Major Vascular Events in Chronic Kidney Disease (CKD)</em></p><p>The Study of Heart and Renal Protection (SHARP) was a multi-national, randomised, placebo- controlled, double-blind study conducted in 9438 patients with chronic kidney disease, a third of whom were on dialysis at baseline. A total of 4650 patients were allocated to a fixed dose combination of Ezetrol 10 mg with simvastatin 20 mg and 4620 to placebo, and followed for a median of 4.9 years. Patients had a mean age of 62 and 63 % were male, 72 % Caucasian, 23 % diabetic and, for those not on dialysis, the mean estimated glomerular filtration rate (eGFR) was</p><p>26.5 ml/min/1.73 m2. &nbsp;There &nbsp;were &nbsp;no &nbsp;lipid &nbsp;entry &nbsp;criteria. &nbsp;Mean &nbsp;LDL-C &nbsp;at &nbsp;baseline &nbsp;was</p><p>108 mg/dL. After one year, including patients no longer taking study medication, LDL-C was reduced 26 %&nbsp; relative&nbsp; to placebo by simvastatin 20 mg alone and 38 % by Ezetrol 10 mg combined with simvastatin 20 mg.</p><p>&nbsp;</p><p>The SHARP protocol-specified primary comparison was an intention-to-treat analysis of &quot;major vascular events&quot; (MVE; defined as nonfatal MI or cardiac death, stroke, or any revascularisation procedure) in only those patients initially randomised to the Ezetrol combined with simvastatin (n=4193) or placebo (n=4191) groups. Secondary analyses included the same composite analyzed for the full cohort randomised (at study&nbsp; baseline or at year 1) to Ezetrol combined with simvastatin (n=4650) or placebo (n=4620) as well as the components of this composite.</p><p>&nbsp;</p><p>The primary endpoint analysis showed that Ezetrol combined with simvastatin significantly reduced the risk of major vascular events (749 patients with events in the placebo group vs. 639 in the Ezetrol combined with simvastatin group) with a relative risk reduction of 16 % (p=0.001).</p><p>&nbsp;</p><p>Nevertheless, this study design did not allow for a separate contribution of the monocomponent ezetimibe to efficacy to significantly reduce the risk of major vascular events in patients with CKD.</p><p>&nbsp;</p><p>The individual components of MVE in all randomised patients are presented in Table 2. Ezetrol combined with simvastatin significantly reduced the risk of stroke and any revascularisation,</p><p>&nbsp;</p><p>with non-significant numerical differences favouring Ezetrol combined with simvastatin for nonfatal MI and cardiac death.</p><p>&nbsp;</p><p>Table 2</p><p>Major Vascular Events by Treatment Group in all randomised patients in SHARPa</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="height:87.25pt; vertical-align:top; width:139.15pt"><p>&nbsp;</p><p><u>Outcome</u></p></td><td style="height:87.25pt; vertical-align:top; width:81.3pt"><p>Ezetrol 10 mg combined with simvastatin 20 mg (N=4650)</p></td><td style="height:87.25pt; vertical-align:top; width:73.4pt"><p><u>Placebo</u> (N=4620)</p></td><td style="height:87.25pt; vertical-align:top; width:94.9pt"><p><u>Risk Ratio</u></p><p><u>(95% </u><u>CI)</u></p></td><td style="height:87.25pt; vertical-align:top; width:56.1pt"><p><u>P-value</u></p></td></tr><tr><td style="height:26.75pt; vertical-align:top; width:139.15pt"><p>Major Vascular Events</p></td><td style="height:26.75pt; vertical-align:top; width:81.3pt"><p>701 (15.1%)</p></td><td style="height:26.75pt; vertical-align:top; width:73.4pt"><p>814 (17.6%)</p></td><td style="height:26.75pt; vertical-align:top; width:94.9pt"><p>0.85 (0.77-0.94)</p></td><td style="height:26.75pt; vertical-align:top; width:56.1pt"><p>0.001</p></td></tr><tr><td style="height:20.65pt; vertical-align:top; width:139.15pt"><p>Nonfatal MI</p></td><td style="height:20.65pt; vertical-align:top; width:81.3pt"><p>134 (2.9%)</p></td><td style="height:20.65pt; vertical-align:top; width:73.4pt"><p>159 (3.4%)</p></td><td style="height:20.65pt; vertical-align:top; width:94.9pt"><p>0.84 (0.66-1.05)</p></td><td style="height:20.65pt; vertical-align:top; width:56.1pt"><p>0.12</p></td></tr><tr><td style="height:20.65pt; vertical-align:top; width:139.15pt"><p>Cardiac Death</p></td><td style="height:20.65pt; vertical-align:top; width:81.3pt"><p>253 (5.4%)</p></td><td style="height:20.65pt; vertical-align:top; width:73.4pt"><p>272 (5.9%)</p></td><td style="height:20.65pt; vertical-align:top; width:94.9pt"><p>0.93 (0.78-1.10)</p></td><td style="height:20.65pt; vertical-align:top; width:56.1pt"><p>0.38</p></td></tr><tr><td style="height:20.65pt; vertical-align:top; width:139.15pt"><p>Any Stroke</p></td><td style="height:20.65pt; vertical-align:top; width:81.3pt"><p>171 (3.7%)</p></td><td style="height:20.65pt; vertical-align:top; width:73.4pt"><p>210 (4.5%)</p></td><td style="height:20.65pt; vertical-align:top; width:94.9pt"><p>0.81 (0.66-0.99)</p></td><td style="height:20.65pt; vertical-align:top; width:56.1pt"><p>0.038</p></td></tr><tr><td style="height:34.8pt; vertical-align:top; width:139.15pt"><p>Non-hemorrhagic Stroke</p></td><td style="height:34.8pt; vertical-align:top; width:81.3pt"><p>131 (2.8%)</p></td><td style="height:34.8pt; vertical-align:top; width:73.4pt"><p>174 (3.8%)</p></td><td style="height:34.8pt; vertical-align:top; width:94.9pt"><p>0.75 (0.60-0.94)</p></td><td style="height:34.8pt; vertical-align:top; width:56.1pt"><p>0.011</p></td></tr><tr><td style="height:34.8pt; vertical-align:top; width:139.15pt"><p>Hemorrhagic Stroke</p></td><td style="height:34.8pt; vertical-align:top; width:81.3pt"><p>45 (1.0%)</p></td><td style="height:34.8pt; vertical-align:top; width:73.4pt"><p>37 (0.8%)</p></td><td style="height:34.8pt; vertical-align:top; width:94.9pt"><p>1.21 (0.78-1.86)</p></td><td style="height:34.8pt; vertical-align:top; width:56.1pt"><p>0.40</p></td></tr><tr><td style="height:20.65pt; vertical-align:top; width:139.15pt"><p>Any Revascularisation</p></td><td style="height:20.65pt; vertical-align:top; width:81.3pt"><p>284 (6.1%)</p></td><td style="height:20.65pt; vertical-align:top; width:73.4pt"><p>352 (7.6%)</p></td><td style="height:20.65pt; vertical-align:top; width:94.9pt"><p>0.79 (0.68-0.93)</p></td><td style="height:20.65pt; vertical-align:top; width:56.1pt"><p>0.004</p></td></tr><tr><td style="height:34.8pt; vertical-align:top; width:139.15pt"><p>Major Atherosclerotic Events (MAE)b</p></td><td style="height:34.8pt; vertical-align:top; width:81.3pt"><p>526 (11.3%)</p></td><td style="height:34.8pt; vertical-align:top; width:73.4pt"><p>619 (13.4%)</p></td><td style="height:34.8pt; vertical-align:top; width:94.9pt"><p>0.83 (0.74-0.94)</p></td><td style="height:34.8pt; vertical-align:top; width:56.1pt"><p>0.002</p></td></tr></tbody></table><p>aIntention-to-treat analysis on all SHARP patients randomised to Ezetrol combined with simvstatin or placebo either at baseline or year 1</p><p>b MAE; defined as the composite of nonfatal myocardial infarction, coronary death, non-hemorrhagic stroke, or any revascularisation</p><p>&nbsp;</p><p>The absolute reduction in LDL cholesterol achieved with Ezetrol combined with simvastatin was lower among patients with a lower baseline LDL-C (&lt;2.5 mmol/l) and patients on dialysis at baseline than the other patients, and the corresponding risk reductions in these two groups were attenuated.</p><p>&nbsp;</p><p><em>Homozygous</em><em> </em><em>Familial</em><em> </em><em>Hypercholesterolaemia</em><em> </em><em>(HoFH)</em></p><p>A double-blind, randomised, 12-week study enrolled 50 patients with a clinical and/or genotypic diagnosis of HoFH, who were receiving atorvastatin or simvastatin (40 mg) with or without concomitant LDL apheresis. Ezetrol co-administered with atorvastatin (40 or 80 mg) or simvastatin (40 or 80 mg), significantly reduced LDL-C by 15 % compared with increasing the dose of simvastatin or atorvastatin monotherapy from 40 to 80 mg.</p><p>&nbsp;</p><p><em>Homozygous</em><em> </em><em>Sitosterolaemia</em><em> </em><em>(Phytosterolaemia)</em></p><p>&nbsp;</p><p>In a double-blind, placebo-controlled, 8-week trial, 37 patients with homozygous sitosterolaemia were randomised to receive Ezetrol 10 mg (n=30) or placebo (n=7). Some patients were receiving other treatments (e.g., statins, resins). Ezetrol significantly lowered the two major plant sterols, sitosterol and campesterol, by 21 % and 24 % from baseline, respectively. The effects of decreasing sitosterol on morbidity and mortality in this population are not known.</p><p>&nbsp;</p><p><em>Aortic</em><em> </em><em>Stenosis</em></p><p>The Simvastatin and Ezetimibe for the Treatment of Aortic Stenosis (SEAS) study was a multi- center, double-blind, placebo-controlled study with a median duration of 4.4 years conducted in 1873 patients with asymptomatic aortic stenosis (AS), documented by Doppler-measured aortic peak flow velocity within the range of 2.5 to 4.0 m/s. Only patients who were considered not to require statin treatment for purposes of reducing atherosclerotic cardiovascular disease risk were enrolled. Patients were randomised 1:1 to receive placebo or co-administered ezetimibe 10 mg and simvastatin 40 mg daily.</p><p>&nbsp;</p><p>The primary endpoint was the composite of major cardiovascular events (MCE) consisting of cardiovascular death, aortic valve replacement (AVR) surgery, congestive heart failure (CHF) as a result of progression of AS, nonfatal myocardial infarction, coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI), hospitalisation for unstable angina, and nonhaemorrhagic stroke. The key secondary endpoints were composites of subsets of the primary endpoint event categories.</p><p>&nbsp;</p><p>Compared to placebo, ezetimibe/simvastatin 10/40 mg did not significantly reduce the risk of MCE. The primary outcome occurred in 333 patients (35.3%) in the ezetimibe / simvastatin group and in 355 patients (38.2%) in the placebo group (hazard ratio in the ezetimibe / simvastatin group, 0.96; 95% confidence interval, 0.83 to 1.12; p = 0.59). Aortic valve replacement was performed in 267 patients (28.3%) in the ezetimibe / simvastatin group and in 278 patients (29.9%) in the placebo group (hazard ratio, 1.00; 95% CI, 0.84 to 1.18; p = 0.97). Fewer patients had ischemic cardiovascular events in the ezetimibe / simvastatin group (n=148) than in the placebo group (n=187) (hazard ratio, 0.78; 95% CI, 0.63 to 0.97; p = 0.02), mainly because of the smaller number of patients who underwent coronary artery bypass grafting.</p><p>&nbsp;</p><p>Cancer occurred more frequently in the ezetimibe / simvastatin group (105 versus 70, p = 0.01). The clinical relevance of this observation is uncertain as in the bigger SHARP trial the total number of patients with any incident cancer (438 in the ezetimibe/ simvastatin versus 439 placebo group) did not differ. In addition, in the IMPROVE-IT trial the total number of patients with any new malignancy (853 in the ezetimibe/simvastatin group versus 863 in the simvastatin group) did not differ significantly and therefore the finding of SEAS trial could not be confirmed by SHARP or IMPROVE-IT.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p><u>Absorption</u></p><p>After oral administration, ezetimibe is rapidly absorbed and extensively conjugated to a pharmacologically active phenolic glucuronide (ezetimibe-glucuronide). Mean maximum plasma</p><p>&nbsp;</p><p>concentrations (Cmax) occur within 1 to 2 hours for ezetimibe-glucuronide and 4 to 12 hours for ezetimibe. The absolute bioavailability of ezetimibe cannot be determined as the compound is virtually insoluble in aqueous media suitable for injection.</p><p>&nbsp;</p><p>Concomitant food administration (high fat or non-fat meals) had no effect on the oral bioavailability of ezetimibe when administered as Ezetrol 10-mg tablets. Ezetrol can be administered with or without food.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Ezetimibe and ezetimibe-glucuronide are bound 99.7 % and 88 to 92 % to human plasma</p><p>proteins, respectively.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Ezetimibe is metabolised primarily in the small intestine and liver via glucuronide conjugation (a phase II reaction) with subsequent biliary excretion. Minimal oxidative metabolism (a phase I reaction) has been observed in all species evaluated. Ezetimibe and ezetimibe-glucuronide are the major drug-derived compounds detected in plasma, constituting approximately 10 to 20 % and 80 to 90 % of the total drug in plasma, respectively. Both ezetimibe and ezetimibe-glucuronide are slowly eliminated from plasma with evidence of significant enterohepatic recycling. The half- life for ezetimibe and ezetimibe-glucuronide is approximately 22 hours.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Following oral administration of 14C-ezetimibe (20 mg) to human subjects, total ezetimibe accounted for approximately 93 % of the total radioactivity in plasma. Approximately 78 % and 11 % of the administered radioactivity were recovered in the faeces and urine, respectively, over a 10-day collection period. After 48 hours, there were no detectable levels of radioactivity in the plasma.</p><p>&nbsp;</p><p><u>Special Populations</u></p><p><em>Paediatric</em><em> </em><em>population</em></p><p>The pharmacokinetics of ezetimibe are similar between children &ge;6 years and adults. Pharmacokinetic data in the paediatric population &lt; 6 years of age are not available. Clinical experience in paediatric and adolescent patients includes patients with HoFH, HeFH, or sitosterolaemia.</p><p>&nbsp;</p><p><em>Older</em><em> </em><em>people</em></p><p>Plasma concentrations for total ezetimibe are about 2-fold higher in the elderly (&sup3; 65 years) than in the young (18 to 45 years). LDL-C reduction and safety profile are comparable between elderly and young subjects treated with Ezetrol. Therefore, no dosage adjustment is necessary in the elderly.</p><p>&nbsp;</p><p><em>Hepatic</em><em> </em><em>impairment</em></p><p>After a single 10-mg&nbsp; dose of ezetimibe,&nbsp; the mean&nbsp; AUC for total&nbsp; ezetimibe was&nbsp; increased approximately 1.7-fold in patients with mild hepatic impairment (Child-Pugh score 5 or 6), compared to healthy subjects. In a 14-day, multiple-dose study (10 mg daily) in patients with</p><p>&nbsp;</p><p>moderate hepatic impairment (Child-Pugh score 7 to 9), the mean AUC for total ezetimibe was increased approximately 4-fold on Day 1 and Day 14 compared to healthy subjects. No dosage adjustment is necessary for patients with mild hepatic impairment. Due to the unknown effects of the increased exposure to ezetimibe in patients with moderate or severe (Child-Pugh score &gt; 9) hepatic impairment, Ezetrol is not recommended in these patients (see section 4.4).</p><p>&nbsp;</p><p><em>Renal</em><em> </em><em>impairment</em></p><p>After a single 10-mg dose of ezetimibe in patients with severe renal disease (n=8; mean CrCl</p><p>&le; 30 ml/min/1.73 m2), the mean AUC for total ezetimibe was increased approximately 1.5-fold, compared to healthy subjects (n=9). This result is not considered clinically significant. No dosage adjustment is necessary for renally impaired patients.</p><p>&nbsp;</p><p>An additional patient in this study (post-renal transplant and receiving multiple medications, including ciclosporin) had a 12-fold greater exposure to total ezetimibe.</p><p>&nbsp;</p><p><em>Gender</em></p><p>Plasma concentrations for total ezetimibe are slightly higher (approximately 20 %) in women than in men. LDL-C reduction and safety profile are comparable between men and women treated with Ezetrol. Therefore, no dosage adjustment is necessary on the basis of gender.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Animal studies on the chronic toxicity of ezetimibe identified no target organs for toxic effects. In dogs treated for four weeks with ezetimibe (&ge; 0.03 mg/kg/day) the cholesterol concentration in the cystic bile was increased by a factor of 2.5 to 3.5. However, in a one-year study on dogs given doses of up to 300 mg/kg/day no increased incidence of cholelithiasis or other hepatobiliary effects were observed. The significance of these data for humans is not known. A lithogenic risk associated with the therapeutic use of Ezetrol cannot be ruled out.</p><p>&nbsp;</p><p>In co-administration studies with ezetimibe and statins the toxic effects observed were essentially those typically associated with statins. Some of the toxic effects were more pronounced than observed during treatment with statins alone. This is attributed to pharmacokinetic and pharmacodynamic interactions in co-administration therapy. No such interactions occurred in the clinical studies. Myopathies occurred in rats only after exposure to doses that were several times higher than the human therapeutic dose (approximately 20 times the AUC level for statins and 500 to 2000 times the AUC level for the active metabolites).</p><p>&nbsp;</p><p>In a series of <em>in vivo </em>and <em>in vitro </em>assays ezetimibe, given alone or co-administered with statins, exhibited no genotoxic potential. Long-term carcinogenicity tests on ezetimibe were negative.</p><p>&nbsp;</p><p>Ezetimibe had no effect on the fertility of male or female rats, nor was it found to be teratogenic in rats or rabbits, nor did it affect prenatal or postnatal development. Ezetimibe crossed the placental barrier in pregnant rats and rabbits given multiple doses of 1000 mg/kg/day. The co- administration of ezetimibe and statins was not teratogenic in rats. In pregnant rabbits a small number of skeletal deformities (fused thoracic and caudal vertebrae, reduced number of caudal</p><p>&nbsp;</p><p>vertebrae) &nbsp;were &nbsp;observed. &nbsp;The &nbsp;co-administration &nbsp;of &nbsp;ezetimibe &nbsp;with &nbsp;lovastatin &nbsp;resulted &nbsp;in embryolethal effects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Croscarmellose sodium Lactose monohydrate Magnesium stearate Microcrystalline cellulose Povidone (K29-32) Sodium laurilsulfate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 Years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Unit Dose peelable blisters of clear polychlorotrifluoroethylene/PVC&nbsp; sealed to vinyl coated aluminium backed with paper and polyester in packs of 7, 10, 14, 20, 28, 30, 50, 98, 100, or</p><p>300 tablets.</p><p>&nbsp;</p><p>Push-through blisters of clear polychlorotrifluoroethylene/PVC sealed to vinyl coated aluminium in packs of 7, 10, 14, 20, 28, 30, 50, 84, 90, 98, 100, or 300 tablets.</p><p>&nbsp;</p><p>Unit dose push-through blisters of clear polychlorotrifluoroethylene/PVC coated aluminium in packs of 50, 100 or 300 tablets.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>No special requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorization Holder:
Merck Sharp & Dohme Ltd. Hertford
Road, Hoddesdon
Hertfordshire EN11 9BU
United Kingdom

Manufacturer:
MSD International GmbH (Puerto Rico Branch) LLC,
Las Piedras Operations , Pridco Industrial Park,
State Road no. 183, Las Piedras, Puerto Rico
00771, Puerto Rico

Packed by:
Pharma Pharmaceutical Industries,
Second Industrial Area,
P.O. Box 11351 Riyadh, Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3	February 2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>